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Abstract 
 
As part of the ‚COMPACT’ (Collaboration on the Optimization of Macromolecular 
Pharmaceutical Access to Cellular Targets) project a consortium of partners from 
academic and industrial research set the aim of developing a carrier system for the 
transport of siRNA (small interfering RNA) into the lung to overcome the pulmonary 
barrier. For this purpose, an established nanoparticulate system consisting of two 
polymers, PLGA poly(lactide-co-glycolide) and Chitosan, was applied and optimized 
concerning particle characteristics (size, distribution, and charge) potential 
automation and upscaling processes. 
Within the development of the second generation of biodegradable drug delivery 
systems, a novel combination of Protamine + PLGA and CatStarch (a synthesized 
water-soluble cationic starch) + PLGA was used and characterized with regards to its 
application. 
In vitro studies were performed to investigate the carriers biocompatibility 
(cytotoxicity and immunogenicity) and efficacy (cellular uptake, localization 
andtransfection). Within this examination, a method to show knock-down results 
without the availability of cost-intensive stable transfected cell lines was developed. 
  
Kurzzusammenfassung 
X 
 
Kurzzusammenfassung 
 
Im Rahmen des „COMPACT“ (Collaboration on the Optimisation of Macromolecular 
Pharmaceutical Access to Cellular Targets) Projektes wurde in Kooperation mit 
Partnern aus Industrie und universitärer Forschung das Ziel gesetzt, einen Träger für 
den Transport von siRNA (small interfering RNA) in die Lunge zu entwickeln, um die 
Lungenbarriere zu überwinden. Zu diesem Zweck wurde auf ein bestehendes 
nanopartikuläres System bestehend aus zwei Polymeren, PLGA (Polylactid-co-
Glycolid) und Chitosan, aufgebaut und die Herstellung bezüglich 
Partikeleigenschaften (Größe, Partikelgrößenverteilung und Ladung), möglicher 
Automatisierungs- und späterer Upscaling-Prozesse optimiert.   
Bei der Entwicklung einer zweiten Generation an bioabbaubaren 
Wirkstoffträgersystemen wurde eine neuartige Kombination aus Protamin und PLGA 
und CatStarch (eine synthetisierte wasserlösliche kationische Stärke) und PLGA 
verwendet und unter applikationsspezifischer Gesichtspunkten charakterisiert.  
Zur Beschreibung der Trägersysteme gehörten neben in vitro Untersuchungen zur 
Zelltoxizität, Immunogenität, Zellaufnahme und Lokalisierung, die Überprüfung der 
jeweiligen Transfektionseffizienz. Innerhalb dieser Versuche konnte eine Methode 
entwickelt werden, die die Darstellung von knock-down Prozessen ohne 
Vorhandensein einer kostenintensiven stabil transfizierten Zelllinie ermöglicht. 
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Chapter 1 - General introduction 
1.1 Biomacromolecules as pharmaceutical ingredients 
1.1.1 Definition of biomacromolecules and their impact on 
the market 
The definition of biomacromolecules consists of the combination of the terms 
biological molecules (or biomolecules) and macromolecules. Biomolecules include all 
chemical structures which can be found in living organisms and all types of their 
metabolites, this includes hormones, proteins, lipids, nucleic acids and other natural 
products (e.g. cellulose, rubber). Macromolecules, however, describe all large, usual 
molecules with Mw (‘relative’ molecular weight/mass) of more than 10,000 [1], 
irrespective of their synthetic or natural origin.  
The combined term biomacromolecules implies a limited group of only large 
biomolecules. Polymeric structures consisting of smaller units or monomers (e.g. 
proteins and nucleic acids) are part of this definition as well as non-polymeric lipids. 
Therefore, these molecules have different (not typically ‘drug like’) characteristics and 
are substantial more dependent on delivery technologies than smaller molecules. 
Biomacromolecules as a powerful new class of active pharmaceutical ingredients 
(API) offer an improvement in drug efficiency and safety (low capability of unintended 
side-effects) resulting from an exquisite specificity and a highly selective mode of 
action. With this it is possible to intervene directly in disease pathways. Nevertheless 
the in vivo stability and the lack of cellular uptake (insufficient capability to reach 
intracellular targets: essential particularly for nucleic acids) are some restrictions 
which need to be considered [2-4]. Therefore new barrier-crossing formulations are 
required beside the development of new APIs. 
 In the range of proteins and peptides, many candidates e.g. insulin and monoclonal 
antibodies (Humalog®, Humira®; proteins) or the gonadotropin-releasing hormone 
Leuprorelin (Lupron®; peptide) just to mention some are already available on the 
market [5-8]. Currently, Humira® even ranks at the very top position of drugs with the 
highest sale numbers. This perspective a high target specificity and a low potential to 
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fail in late developmental stages are reasons why the pharmaceutical industry count 
on biomacromolecules. 
Till now, the FDA (Food and Drug Administration) approved two antisense 
oligonucleotides (ASO) Fomivirsen (Vitravene®) against cytomegalovirus retinitis and 
Mipomersen (Kynamro®), used for treating homozygous familial 
hypercholesterolemia. These intravitreal or subcutaneous applied medicines from 
Ionis Pharmaceuticals, formerly known as ISIS Pharmaceuticals [9] were the first 
antisense therapeutics on the US-market; to date, the European Medicine Agency 
(EMA) however refused the approval of Mipomersen [10] due to relatively high 
dropout rates in the proband group. 
Currently, approximate 30 therapeutics can be found in clinical trials which include 
two intravenously administered siRNA-based formulations from Alnylam 
Pharmaceuticals against Transthyretin-mediated amyloidosis [11].  Both are enrolled 
in phase III trials: Revusiran within the ENDEAVOUR study [12] and Patisiran within 
the study APOLLO [13]. First statements concerning the outcome can prospectively 
be expected in 2018 [14]. Notwithstanding rapid advances in research, no 
non-invasive antisense oligonucleotides are present on the market or in late-stage 
studies.  
Biomacromolecules in general have a great potential which could be exploit much 
better if more suitable carriers for intracellular targeted delivery were available. Within 
the COMPACT project (see section 1.4) different delivery technologies were used to 
enable a transport of biomacromolecules through the epithelium. Within this thesis 
one side project of COMPACT will be presented and focuses on the pulmonary 
delivery of a delimited group of nucleic acids, in specific siRNA. 
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1.1.2 Gene suppression via RNA interference 
Eukaryotic cells have sophisticated antisense mechanisms to regulate or suppress 
gene expression [15, 16]. One very important post-transcriptional [17, 18] pathway to 
inhibit the function of a target RNA is the mechanism of RNA interference (RNAi) 
[19], which was discovered in 1998 by Fire et al. [20]. Only a few years later in 2006, 
the Nobel Prize in Physiology or Medicine was awarded to Andrew Z. Fire and Craig 
C. Mello “for their discovery of RNA interference – gene silencing by double-stranded 
RNA” [21].  
Before then studies demonstrated possible gene silencing caused by antisense [22] 
and remarkable sense [23] strands. These results were inconsistent so that 
interfering effects could not be explained by the simple pairing of antisense RNA to 
mRNA [24]. Within their work Fire et al. were able to observe an enhanced silencing 
effect of double-stranded RNA (dsRNA) in contrast to sole sense or antisense 
strands [20].  This new insight and further conclusions about the specificity of dsRNA 
to homologous mRNA and the loss of mRNA (degradation) put the pieces together 
and led to the explanation of the RNAi mechanism. 
The RNA interference by mRNA cleavage or translational repressions is mediated by 
the same protein complex, called RISC (RNA-induced silencing complex). The 
crucial template for the interference, however, can be either siRNA or miRNA. SiRNA 
(small interfering RNA) is a short double-stranded RNA oligonucleotide with a 
prevalent length of 21-23 nucleotides (nt) [25] with a two nucleotide 3’-overhang on 
each strand and leads to mRNA cleavage. In contrast, miRNA (micro RNA) [26-28] is 
a single-stranded RNA oligonucleotide with a prevalent length of 19-25 nt) [29] and 
leads to translational repression or mRNA cleavage. The crucial small non-coding 
oligonucleotides for RNAi pursue in general the same mechanism, but slightly differ 
in their emergence and binding to target mRNA (see Figure 1.1).  
Figure 1.1: RNA interference by siRNA and miRNA 
complex, AGO2: argonaute protein 
compiled based on Lam 2015 [30]
Chapter 1 
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siRNA pathway 
In the nucleus siRNA can arise from an endogenous source naturally produced in the 
body or by viral genetic material. It is primary known as a defense mechanism 
against viruses and genome transposons. Therefore, a degradation of target mRNA 
is essential. The transcription of both ‘sense’ and ‘antisense’ RNA from the same loci 
results in the assembly of long double stranded RNA (dsRNA). After the transport of 
dsRNA into the cytoplasm via the nuclear pore complex (NPC), the enzyme “Dicer”, a 
RNase-III-like endoribonuclease [19, 33], starts with a subsequent cleavage of the 
RNA molecule. An exogenous source is the direct injection or transfection of 
synthetic siRNA [34]. The synthesis of short RNA molecules is an easy operation to 
create effective active ingredients. Once in the cytoplasm, the siRNA is creating an 
RNA-induced silencing complex (RISC). Within this multiprotein complex, the double 
strand will be unwound and separated (Helicase function) [16] so that only the 
antisense (or guide) strand is remaining. The sense (or passenger) strand will be 
degraded [29] whereas the antisense strand incorporated in the RISC complex binds 
completely complementary to one target mRNA. The Argonaut (AGO2) as the major 
catalytic part of the RISC complex causes cleavage of the mRNA (RNase H 
function). Thus, the translation of the mRNA into a protein is inhibited or the mRNA 
itself destroyed. 
 
miRNA pathway 
MiRNAs are products of dsRNAs encoded in genes of our genome and support the 
control of gene expression and cell functions (e.g. differentiation, development). DNA 
is transcribed (via polymerase II) into single-stranded RNA (ssRNA) and converted 
into dsRNA (pri-miRNA) [35] due to the sequence complementary. First, the 
RNase-III-enzyme “Drosha” [36] cuts the pri-miRNA into smaller fragments 
(pre-miRNA) [37], then “Exportin 5” guides the pre-miRNA from the nucleus into the 
cytoplasm. There, the enzyme “Dicer” cuts off the stem-loop [38] and forms a 
miRNA:miRNA* duplex [39, 40]. After binding to RISC, the passenger strand is 
discarded, and the mature single-stranded miRNA (guide strand) within the RISC 
complex binds partially complementary to multiple mRNAs via short complementary 
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sections (“seed region”: 2-7 nt) [41, 42]. In this way the mRNA is degraded, cleaved 
(only by a high level of complementarity) or its translation is repressed.  
Although siRNA and miRNA have different functions, their respective pathway 
appears very similar. Both use the same silencing complex (RISC) to receive a 
ssRNA template and to reach target mRNA. Based on the high similarity of siRNA 
and miRNA similar carrier systems can be used to deliver nucleic acids (see 
section 2.1). Sometimes in the context of gene silencing the terms short hairpin RNA 
[43] (shRNA), piwi-interacting RNA (piRNA) and repeat-associated small interfering 
RNA (rasiRNA) may be used. ShRNAs are foreign vector-based RNAs, serve as 
precursors [44, 45] and assimilate into the miRNA pathway [46]. PiRNAs are small 
non-coding RNAs (24-31 nt in length) interacting with P-element induced wimpy 
testis (PIWI) proteins and occur in germline cells [44, 47, 48]; rasiRNAs are merely a 
group of piRNAs [49, 50]. 
Therapeutic siRNA often looks like a degradation product (sometimes longer 
dsRNAs) of the enzyme ‘dicer’. This is the reason why siRNA only need to be 
delivered into the cytosol to be effective. Especially the targeted compartment needs 
to be considered when developing a specific delivery system. Otherwise highly 
effective drugs are not able to show their mode of action. 
 
1.2 The lung as a target  
1.2.1 Morphology and anatomy of the human lung 
The lung is a part of the lower respiratory tract and the responsible organ for gas 
exchange. In humans (and mammals in general) two lungs are located in the thoracic 
cavity. The conductive section comprises the windpipe (trachea), which branches into 
two main bronchi and separates the right lung (pulmo dexter) with three lobes from 
the left lung (pulmo sinister) with two lobes. The respiratory section comprises the 
cartilaginous bronchi branching again into smaller bronchioles, finally ending into 
alveolar ducts with a terminal collection of alveoli. The alveoli consist of flattened 
epithelial cells and are surrounded by a mesh of capillaries to ensure the exchange 
of oxygen versus carbon dioxide (via diffusion). An adult pair of human lungs 
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contains approximately 700 million alveoli. With a diameter of ~200 µm the total 
respiratory surface area estimates about 90 m2 [51]. Therefore, the pulmonary route 
represents an interesting target structure for the deposition of drugs in current 
research activities. 
The gross anatomy of the lung differs from the bronchial to the alveolar level as well 
as the microscopic anatomy of these regions (see Figure 1.2, adapted from Klein 
2011 and modified from Ochs/Weibel 2008).  
 
Figure 1.2: Scheme of the respiratory wall, divided in three main parts: mucus-producing bronchus, 
bronchioles and surfactant-producing alveolus. Adapted from Klein 2011 and modified from Ochs and 
Weibel 2008. 
The upper rigid part, trachea and bronchus, consists of a thick fibro-cartilaginous 
layer with many embedded glands, a smooth muscle cell layer and the lamina propria 
(connective fibro-elastic tissue and blood vessels). The epithelium implies ciliated 
pseudostratified epithelial cells, mucus-producing goblet cells and basal cells [52]. 
The intermediate bronchioles contain no longer cartilage cells and glands but more 
blood vessels and capillaries. The epithelium has still ciliated but cuboidal epithelial 
cells and secretory dome-shaped Clara cells (also known as club cells or bronchiolar 
exocrine cells) [53]. The terminal alveolus mainly consists of a mono-layer-mosaic of 
flat (~ 0.2 - 0.3 µm thick) structure-lending Alveolar Type-I (AT I) epithelial cells that 
cover roughly 90% of the total alveolar surface 
capillaries embedded in elastic and collagenous fibers without any muscle cells
remaining part occupy granular 
secrete surfactant to avoid collapsed alveoli by the reduction of 
57]. Especially the presence of a mono
treatment of appropriate lung diseases feasible.   
 
1.2.2 Pulmonary diseases and current medical applications
Following the World Health Organization
Prevention and Control, many diseases 
obstructive pulmonary disease (COPD), pneumonia and lung cancer are just 
the most common ones. The 
Lung White Book with the latest data about respiratory deaths in European countries
[58] (see Figure 1.3). 
Figure 1.3 Deaths caused by respiratory conditions in 
percent). ILD: interstitial lung disease; TB: tuberculosis; LRI: lower respiratory infections; COPD: 
chronic obstructive pulmonary di
Mortality Databases. Adopted from webpage: http://www.erswhitebook.org/chapters/the
lung-disease/; 25.04.2016. 
*countries with available full ICD-
Chapter 1 
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surface tension 
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 and the European Centre for Disease 
may affect the human lung.
European Respiratory Society published the 
selected European Union countries
sease from World Health Organization World and Europe Detailed 
10 coding diagnoses for both hospital admissions and deaths
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The major proportion of lethal pulmonary diseases can be reduced to lung cancers, 
pneumonia, COPD, and bronchiectasis. Therefore a curative therapy of these 
maladies is particularly relevant.  
To treat respiratory disorders in general, it is possible to hit the lung via the systemic 
(“blood-to-lung”) or topical (“air-to-lung”) route. A systemic application of several 
drugs e.g. chemotherapeutics was established, but due to relatively high required 
doses (caused by high protein binding or interactions with Cytochrome-P-450) 
adverse effects like tissue necrosis, hematological toxicity or cytostatic induced 
vomiting may endanger the success of a cancer therapy. A standard [59] topical 
therapy for the symptomatic treatment of Asthma [60] and COPD [59, 61] are 
bronchodilators (e.g. Formoterol, Tiotropium bromide) and corticosteroids 
(Budesonide).  
It is obvious that a great need for inhalable drugs is present. Biopharmaceuticals and 
siRNA may reach new (not available with small molecule drugs) target proteins and 
enable an easier personalized medicine (e.g. in tumor therapy). First studies with 
naked siRNA showed an insufficient potency. Therefore, possibilities to maintain the 
stability of a therapeutic agent and to assure a controlled drug release were explored. 
Here, the scientific focus is especially set on nanotechnology and nanoparticle-based 
carrier systems. 
 
1.3 Nanoparticles as a system to overcome biological 
barriers 
1.3.1 Nanoparticles or nanopharmaceuticals - what makes 
the difference? 
Nowadays nanotechnology, the production technology of nanoparticles (NP) [62], 
constitutes in many disciplines from e.g. electronics [63, 64] to life science 
applications [65-68]. Here, the effect of modified properties of nano-materials can be 
turned into a benefit. When talking about nanoparticles, the definition seems to be 
obvious: Nanoparticles are particles (spheres, tubes, fibers or miscellaneous) in the 
nano-scale from 1 nm to 1,000 nm.  This size range is universally accepted, but 
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depending on the field of action or the type of material the described size range may 
differ and comprises particles smaller 1 nm or even larger than 1,000 nm [69]. 
Particularly because the term nanoparticle describes so many different types of 
particles including non-engineered particles (pollutants as side-products of 
incomplete combustion, pathogens, and other airborne particles) it makes sense to 
carry out a classification referred to its application area or occurrence.  
With the beginning of the National Nanotechnology Initiative (NNI) in 2000, the 
terminology in the medical field with the focus on health-sciences changed. “Nano” 
replaced “colloidal” [70] and terms like nanopharmaceuticals, nanomedicines, 
nanodrugs or nano-formulations were utilized more and more frequent. Here, 
nanopharmaceuticals can be described as nanoparticles for therapeutic [71-73] as 
well as diagnostic [74-76] purposes and automatically imply a thorough selection of 
suitable materials manufacturing and characterization methods to ensure an 
adequate drug safety. But that does not necessarily mean the absence of 
nanopharmaceuticals till then. In 1995 the FDA approved Doxil®, a liposomal 
doxorubicin hydrochloride formulation and thus the first nano-drug [77]. Further 
approved nanopharmaceuticals were reviewed by Weissig et al. There, they 
classified nanopharmaceutical drugs due to their structure and material:  liposomes 
(Doxil®, AmBisome®), non-liposomal lipid-based formulations (Abelcet®), PEGylated 
compounds (Pegasys®), nanocrystals (Emend®, Rapamune®), polymer-based 
formulations (Copaxone®), protein-drug conjugates (Abraxane®), surfactant-based 
(Strasorb™) and metal-based (Feridex®) formulations as well as virosomes 
(Gendicine®, approval only in China) [70]. Based on various existing nano-
formulations the development of novel and innovative formulations will continue, and 
future results will follow [78]. 
 
1.3.2 Interactions with cellular and non-cellular barriers 
inside the lungs 
Pulmonary barriers are intended to protect the human body against external 
influences. They do not differentiate between pathogens, pollutants or even 
nanopharmaceuticals and consist of cellular (e.g. epithelial cells)  and non-cellular 
(lining fluid) components [79]
of the central airways (trachea/
region (= alveolus region or deep lung)
particles need to be analy
deposition at the targeted tissue
mechanisms can thwart an 
of particle interactions need to be 
airways (central lung), inhaled 
clearance [80]. This process 
movement in cranial direction 
the velocity of this expulsion ranges
reveals a residence time 
particles need to penetrate 
Depending on the composition of the mucus (amount of water, mucins, proteins, 
lipids…) it consists of a viscous upper gel layer and
[52]. Both together create a 
sizes from 100 nm up to some
 
Figure 1.4 Particle-lung interactions with cellular and non
Carvalho 2014 [91], modified from Ruge 2013 
DDS or particles to/through underlying cells 3: clearance mechanisms.
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efficient delivery of nanopharmaceuticals 
considered (see Figure 1.4). In 
particles are mainly eliminated by 
describes the entrapment of particles in 
accomplished by ciliated epithelial 
 individually between 3-25 mm/min 
of about 6 hours [83]. Within that period
the mucus to reach the epithelial cells underneath
 a lower aqueous sol
complex and heterogeneous mesh with 
 micrometers [84] to hinder particulates
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[79]. 1: deposition on lining fluids 2:
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Regarding the alveolar section, the macrophage clearance removes most of the 
inhaled particles. More than 50 % of them are eliminated after 2-3 hours and nearly 
100 % after 24 hours [85]. Beside AT I and AT II cells joint by tight junctions to 
impede paracellular transport [86, 87] (which is relevant to reach underlying tissue or 
the bloodstream) alveolar macrophages are present in alveolar spaces of the deep 
lung. Triggered by hydrophilic proteins in the surfactant [88, 89] macrophages 
preferably catch and degrade particles in size range of 1-5 µm [90]. If not eliminated 
by the clearance mechanisms APIs or formulations have the chance to reach the 
next barrier, the cell membrane of underlying cells. At this point particulate properties 
like molecular weight, size, charge, lipophilicity, solubility, etc. are decisive criteria for 
further transport.  
Naked siRNA as an example should get into the alveolar cytoplasm. However, due to 
a relatively high molecular weight, large size, hydrophilicity and a negative charge 
(from the phosphate groups of the backbone) the API is not able to easily pass 
anionic cell membranes [92, 93]. To overcome this barrier, cationic 
siRNA-formulations can be designed to enter the cell by endocytosis [94]. (Particles 
with a size around 100 nm may pass the alveolar epithelium [95] whereas bigger 
ones are internalized by endocytic pathways [96].) Contingent on the API and the 
reason for limited uptake and transport a suitable DDS is necessary. 
Considering these barriers and particle-lung interactions in developing novel DDS  it 
is also important not to ignore differing properties of the biological barriers depending 
on the affecting disease and the pathological conditions of the lung [97]. 
 
1.3.3 A combined system of siRNA and nanoparticles as a 
new approach for pulmonary treatment 
Although the general concept of siRNA-based therapeutics remains as a promising 
approach in medical research the development of siRNA-based formulations must 
not be neglected. As almost all of the approved and in clinical trials situated 
antisense oligonucleotides need to be applied via injection - to ensure a locally easy 
access or to target systemically cancer cells [98] - a lack of non-invasive medicines in 
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antisense therapy (e.g. inhalable drugs against alveolar epithelia affecting disorders) 
is apparent. 
Within this work, the focus is basically on the development and evaluation of new 
nanoparticulate systems for the intracellular delivery of siRNA. To ensure a 
successful pulmonary application the implemented materials need to be from the 
outset biocompatible, biodegradable, non-toxic and non-immunogenic - the DDS 
itself needs to be intact stable and reproducible. The approach to create 
nanoparticles to load its surface with siRNA has some clear benefits: Two 
independent preparation steps to create the carrier first and load the cargo on this 
system afterwards in a second step allow a direct correlation in characterizing and 
analyzing the same manufactured batch of the system in a loaded and unloaded 
version. Furthermore, a post-loading has the chance to save limited amounts of 
siRNA and to enable quality control within the formulation process. With the view on 
later industrial perspectives, this systematic to create a DDS holds the opportunity to 
obtain a stable and reproducible (especially important for carriers for high potent 
molecules) and a flexible preparation technique. Here, a later scale-up should be 
possible, to have the capacity when higher amounts are needed and the production 
converts from laboratory scale over pilot scale to production scale. 
Next to polymer-based nanoparticulate systems for the pulmonary delivery of siRNA 
research activities focus on diverse possible carrier systems. Some also use PLGA 
[101] or chitosan [102-104] to create NPs. Others use for instance lipids to create 
nanostructured lipid carriers [105] or create self-assembled micelles [106] and 
cyclodextrin-siRNA nanoplexes [107] to deliver siRNA.  Within COMPACT, project 
partners worked inter alia on surface functionalized lipid polymer hybrid NPs 
(University of Copenhagen, P3) and DARPin-siRNA conjugates or DARPin-siRNA 
pepfect conjugates (University of Vienna, P8). 
 
1.4 Aim of this research study  
Nucleic acid based biopharmaceuticals represent an emergent group in drug 
development. Their therapeutic efficacy however, is restricted due to their limited 
cellular uptake and poor in-vivo stability. Applying non-viral vectors different 
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formulation strategies (e.g. polymeric NPs as a carrier system) may address these 
restrictions. 
This doctoral thesis was part of the collaborative research project COMPACT 
(Collaboration on the Optimization of Macromolecular Pharmaceutical Access to 
Cellular Targets) which was initiated by an association of scientific experts in 
pharmaceutical industry and academia supported by the innovative medicine 
initiative (IMI), a partnership between the European Commission and the European 
Federation of Pharmaceutical Industries and Associations (EFPIA) [99]. To progress 
with a preferably high effectiveness project partners were divided into several 
preconceived work packages (WP) with the focus on the investigation of various 
applications and delivery routes. The development and characterization of drug 
delivery systems (DDS) for proteins or peptides (WP1) and nucleic acids (WP2) for 
different application sites (oral delivery (WP4), brain delivery (WP5), pulmonary 
delivery (WP6), (trans)dermal delivery (WP7)) and in vitro / in vivo testing (preclinical 
validation and identification of transport pathways; WP3) of diverse formulations 
comprised the major goals of the consortium. The framework conditions of this 
research work to develop a drug delivery system for the pulmonary delivery of siRNA 
(WP 2 and 6) needed to be observed by putting emphasis on testing the intracellular 
delivery first. Chitosan coated PLGA NPs as a well-established non-toxic polymeric 
DDS for the delivery of antisense oligonucleotides, 2’-O-metyl-RNA, functioned as a 
starting point for this study (see prior work by Nafee et al. [100]). 
Within this context, 4 major aims of this thesis were identified: 
1 to enhance system robustness by optimizing the particle preparation process 
Determining process parameters of the emulsion-diffusion-evaporation technique 
were identified and optimized to ensure reproducibility, scalability and shelf life of the 
particulate system (chapter 2 - 4).  
 
2 to evaluate the impact of applied cationic polymer on particle characteristics 
and stability 
Three biodegradable and biocompatible cationic polymers with promising transfection 
properties were found to investigate the binding and release behavior by an 
exchange of the respective coating material. In this connection, different material 
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properties (e.g. size, surface charge) were investigated to define diverse particle 
characteristics (chapter 3).  
As the deposition of sole NPs in the deep lung is limited, NP suspensions need to be 
aerosolized. Hence, a particulate system for pulmonary application should be 
retained stable after nebulization by using diverse devices (chapter 4). 
 
3 to perform suitability testing for siRNA delivery 
Functional in-vitro transfection studies build a scientific basis for later in-vivo tests. 
Here, a method to visualize a knock-down on different pulmonary alveolar cells by 
transfected siRNA needed to be invented due to the unavailability of stably 
transfected cell lines (chapter 6) 
 
4 to assess the safety of the DDS in cell-viability and immunogenicity studies 
To investigate a possible harmful potential of the DDS cytotoxicity and 
immunogenicity assays were performed (chapter 5). 
 
Chapter 2 - Optimization of the preparation technique on the basis of chitosan-coated PLGA nanoparticles (1st generation) 
 
 
16 
Chapter 2 - Optimization of the preparation technique on 
the basis of chitosan-coated PLGA nanoparticles 
(1st generation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The author of this thesis made the following contribution to this chapter: 
Planned and performed all experiments related to particle preparation and 
characterization, analyzed all the data from the mentioned studies, interpreted all 
experimental data and wrote the chapter, it not stated otherwise. 
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2.1 Introduction 
As the access of naked nuclease
cytoplasm is restricted nanocarriers may act as promising delivery systems
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PLGA (Figure 2.1), a clinical approved 
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Figure 2.2 Chemical structure of Chitosan
This manufacturing process
PLGA-based NPs with the ability to load
keeping the advantage of a small size distribution and 
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has been published in PNAS (Proceedings of the National Academy of Sciences). Up 
to now, a second manuscript is still in progress. 
1 Institute for Diabetes Research, Independent Young Investigator Group Immune 
Tolerance in Type 1 Diabetes, Helmholtz Diabetes Centre at Helmholtz Zentrum 
München; German Centre for Diabetes Research (DZD) 
2
 Department of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus 
for Medical Research 
 
2.2 NPs preparation 
2.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA, CAS No: 26780-50-7) 
Resomer® RG 752 H from Evonik Industries is a free carbolic acid terminated 
biodegradable synthetic and amorphous copolymer (lactide:glycolide 75:25) with a 
MW 4,000 – 15,000. Degraded and metabolized in the human body (through the citric 
acid cycle) into non-toxic amounts of lactide and glycolide [120]. 
Polyvinyl alcohol (PVOH, CAS No: 9002-89-5) 
Moviol® 4-88 from Kuraray (new grade name Kuraray Poval™ 4-88), is a partially 
saponified (grade of hydrolysis 86.7 – 88.7 mol%) synthetic, biodegradable and water 
soluble (10.0-11.6 residual content of acetyl) polymer with a Mw ~ 31,000 and a high 
standard purity. Within the scope of nanoparticle formation, PVOH is commonly used 
as an emulsifier/surfactant for stabilization of the emulsion in emulsion-solvent 
evaporation technique to form small and uniform particles. 
Chitosan (Cs, CAS No: 9012-76-4) 
Protasan®UP CL 113 from Novamatrix (Sandvika, Norway) is an ultrapure (low level 
of endotoxin and proteins) biopolymer (water-soluble chitosan chloride) in 
accordance with GMP guidelines; ICH Q7; and ISO standards: ISO 9001:2008, 
ISO 13485:2003 and ISO 22442:2007. 75 - 90 % of the acetyl groups are removed. 
The degree of deacetylation (batch no. BP-0806-01: 83 %) was verified by an 
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acid-base-titration according to Yuan et al. [121] with a value within the range of 76.8 
± 1.0 %. Mw 50,000-150,000 g/mol (measured as Chitosan acetate). 
Fluorescein amine isomer I (FA, CAS No: 3326-34-9) or 5-Aminofluorescein = 
6-Amino-3’,6’-dihydroxyspiro[2-benofuran-3’,9’-xanthene]-1-one; used to label 
covalently PLGA polymer (see chapter 2.2.3 for FA-PLGA synthesis) and DiI 
1,1‘-Dioctadecyl-3,3,3‘,3‘-tetramethylindocarbocyanine perchlorate 97 % (CAS No: 
41085-99-8)  was purchased from Sigma-Aldrich, Germany. 
All other used solvents, chemicals and materials are designated in the related 
sections. 
 
2.2.2 PLGA-Chitosan NPs 
Poly (D,L-lactide-co-glycolide (PLGA) based nanoparticles coated with a cationic 
polymer were prepared via the emulsion-diffusion-evaporation technique [100, 113]. 
15 - 25 mg (0.3 – 0.5 % (w/v)) of chitosan was solved in 5 mL of an aqueous 2.5 % 
(w/v) polyvinyl alcohol (PVOH) solution. The organic phase consisting of 100 mg 
PLGA in 5 mL ethyl acetate (EtOAc, CAS No: 141-78-6, Chomasolv® for HPLC 
99.8 % from Sigma-Aldrich, Germany) was added dropwise to the stirring (on 
magnetic stirrer VRW VMS-D from VWR at 900 rpm) aqueous solution to create a 
primary emulsion. After homogenizing with a high-performance dispersing instrument 
(stand dispersion unit: Polytron® PT 2500E; dispersing aggregate: Polytron® PT-DA 
20+/2+ EC-E 192 from Kinematica, Eschbach, Germany) at 15,000 to 17,000 rpm for 
5 – 10 min. ultrapure (type I) purified water (Millipore Milli-Q® Integral water 
purification System, sourced from a Q-POD® unit with a BioPak® filter from Merck, 
Germany) was added to a final volume of 50 mL to let the ethyl acetate evaporate 
overnight (Figure 2.3). The dropwise addition of the organic phase into the aqueous 
phase was implemented in a manual, semi-automatic and automatic manner. For the 
manual dropping method Pasteur pipettes (145 mm or 225 mm) soda-lime-glass ISO 
7712 (Brand GmbH & Co. KG, Germany), for the semi-automatic method a peristaltic 
pump (Minipuls® 2 from Gilson, Middleton, USA) with N needle (from Hamilton ø 0,26 
mm; ø 0,41 mm; ø 0,13 mm) and for the automatic method a syringe pump (Harvard 
Chapter 2 - Optimization of the preparation technique on the basis of chitosan
Apparatus PHD ultra) with a
N needle (from Hamilton ø 
Figure 2.3 Emulsion-Evaporation
 
2.2.3 Flu-labeled NPs
Fluorescent nanoparticles have a great significance 
localization (see chapter 7)
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One advantage of this component 
amine (FA) can easily be coupled
123]. 
 
Figure 2.5 Schematic coupling reaction of fluorescein
FA-PLGA. 
For this purpose 3.07 g 
5-Aminofluorescein (= 
1-one) were solved in 30
1-ethyl-3-(-Dimethylaminopropyl)
remained stirred overnight (up to
carboxylic groups. To precipitate FA
aqueous supernatant was 
Rotina 420R). The generated p
Chomasolv® for HPLC 99.8
washed with ethanol (EtOH, CAS No: 64
FA-PLGA was precipitated. The 
was dried via lyophilization
The resulting FA-PLGA was
exclusion of light at 4 °C or directly used
-coated PLGA nanoparticles (1st generation)
is that the primary amine group 
 with the carboxylic acid of the PLGA polymer 
 amine and PLGA to create fluorescent 
PLGA and 0.0583 g Fluorescein amine isomer
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-PLGA Milli-Q purified water was
discarded after centrifugation (6 min, 6
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Figure 2.6 PLGA (left, white) and FA
To create green fluorescent NPs
(= 20 mg/mL) for non-labeled NPs 
performed analog to non-labeled
chemical destruction of the fluorochrome
Next to the relatively high proneness of fluorescein 
effects [125] this fluorescent dye shows
may cause limitations in some multicolor applications (absorption overlaps 
488 nm spectral line of the 
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not able to differentiate between these two signals, cell and particle signal.
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Figure 2.7 Chemical structure of DiI (1,1‘
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Although it cannot be (easily)
the dye into a PLGA-ethyl acetate solution w
surrounding media [126]. Therefor
added to the solved PLGA 
20 mg/mL PLGA and 2 µM DiI. T
analogously to the prior described emulsion
FA-labeled PLGA particles remain 
fluorescently labeled particle. 
Figure 2.8 Comparison of the absorption (solid line) an
(green) and DiI (yellow). Visualized by Fluorescence 
 
2.3 NPs characterization
2.3.1 Colloidal characteristics
Photon correlation spectroscopy (PCS) was 
Zetasizer Nano Series ZS (Malvern Instruments Inc., UK)
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backscatter (NIBS default).
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(2008). Surface charge derives
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mobility with Zetasizer Nano
ζ-potential is a pH-dependent 
1:10 dilution of Milli-Q water in a standardized quality and a resulting pH value of th
nanoparticle suspension of pH
Ionic strength and pH are critical parameters for colloidal stability. Thus, nanoparticle 
stability was assessed in a set of standard buffers and cell culture media. Results 
were compared to the measurement in only purified water as dispersant.
Phosphate buffered saline (
range from 3.0 – 12.0 and Milli
respectively. PBS Buffer (
KH2PO4) and Krebs-Ringer Buffer (142
10 mM HEPES, 4 mM D-glucose, 1.4
the required pH with 1 M NaOH or 1
All experiments were performed in triplicates.
NPs preparation in physiological buffer
 
2.3.2 Purification techniques
The purification of the DDS is an essential step to 
which might influence further 
e.g. scanning electron microscopy
of the NP morphology is interfered by the
Figure 2.9 SEM-micrograph of non
-coated PLGA nanoparticles (1st generation)
 Series ZS (Malvern Instruments Inc., UK
value: hence the measurement was implemented in 
 5. 
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Various techniques are suitable to remove PVOH from the NP fraction. The most 
obvious way is to centrifugate the nanoparticle suspension (Hettich Rotina 420R 
centrifuge at 24400 x g for 10 min.), decant the supernatant, re-disperse with Milli-Q 
water and repeat this procedure at least three times (method A).  
Centrisart® and Vivaspin® (both from Sartorius Stedim Biotech GmbH, Germany) are 
centrifugal ultrafiltration units with a cellulose triacetate (CTA) or polyether sulfone 
(PES) membrane. The material differs depending on the required molecular weight 
cut-off (MWCO). As Centrisart® I can be used only for small volumes (2.5 mL –
 500 µL) the Vivaspin® 20 device, which can handle volumes up to 20 mL was used. 
As PVOH is a relatively long filamentary molecule, a Vivaspin® 20 unit with a 300,000 
Da PES filter was utilized. The NPs were centrifuged at 6,000 x g for 15 min. (Hettich 
Rotina 420R), Milli-Q water was added to the concentrated NP suspension, and the 
procedure was repeated for three times (method B).   
The Vivaflow® 50 (Sartorius Stedim Biotech GmbH, Germany) is a cross-flow / 
tangential flow system available with a PES or regenerated cellulose (RC) membrane 
with a maximum MWCO of 100,000. The nanoparticle suspension (50 ml) was 
concentrated with a flow rate of approximately 100 mL/min to a final volume of 25 ml 
and diluted with Milli-Q water to the initial volume of 50 ml. This procedure was 
repeated 20 times till 500 ml Milli-Q water were used (method C). Other methods like 
dialysis or asymmetric field flow fractionation (AFFF) are possible for particle 
purification but in this case not applicable. After the washing procedure, the main 
particle characteristics (size, charge, and PdI) were analyzed to assess the impact of 
the procedure on the NPs. 
 
2.3.3 Passive surface loading 
Chitosan-coated NPs were loaded with siRNA in a siRNA: NP ratio of 1:100 and 
1:50. The binding of siRNA onto the particle surface can be described as a passive 
surface loading and underlies the principle of electrostatic attraction of differently 
charged particles (see Figure 2.10). The loading procedure itself and the most 
promising siRNA :NP weight ratios were adopted and partially modified from Nafee et 
al. [127]. 
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Figure 2.10 Scheme of the loading strategy of nucleic acids (siRNA) on PLGA
generation formulation. 
Freeze-dried siRNA provided from GlaxoSmithKline (
nuclease-free water (not DEPC trea
Life Technologies, USA 
1.5 mL/5 mL, PCR clean from Eppendorf AG
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System (50 mL) with a Millipore Experess
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preparation procedure (e.g. dust
suspension was defined via freeze
mass. The final concentration of siRNA
particle mass) achieved by pipetting an appropriate amount of the aqueous siRNA 
solution into the determined volume of NP suspension. To reach optimal binding 
conditions the mixture was 
an orbital shaker. The entire
temperature. 
 
Detection of siRNA 
Next to fluorescent measurements
methods to quantify single and double stranded DNA or RNA
method is suitable for purified nucleotides at 260
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-coated PLGA nanoparticles (1st generation)
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with low concentrations < 1.0 – 1.5 µg/mL. For the 400 µL cuvette (UVette) a dilution 
was necessary because of the limited amount of sample. The following programs 
with predefined factors were eligible: dsDNA 50.0; ss DNA 37.0; RNA 40.0; 
oligo 30.0; x µg/mL = 1A. 
Via an indirect UV measurement with an Infinite® 200 Pro microplate reader (Tecan, 
Switzerland) in UV-Star microplates 96 well, F-Bottom, chimney well, µclear (Greiner 
bio-one, Germany) the loading of the carrier system could be investigated. Here, the 
loaded particles were centrifuged, and the supernatant was analyzed relating to 
remaining free siRNA. 
Fluorescent measurements, however, need specific fluorescent dyes (e.g. SYBR 
Green, Ribo Green, Pico Green, ethidium bromide) which react sensitively with a 
very high precision with the nucleotides. For siRNA detection, SYBR Green II RNA 
staining (directly added to the loading buffer in a final concentration of 1:100 from 
Lonza, Belgium) and ethidium bromide solution (Sigma-Aldrich, USA) were used, and 
the stained gel was illuminated at 300 nm ultraviolet transillumination (peqlab Fusion 
FX). Furthermore, gel electrophoresis was performed to observe surface properties 
and the ability to bind siRNA on the particle surface. 
 
2.3.4 Particle imaging (SEM/SPM) 
As PCS only calculates the mean hydrodynamic diameter of measured 
nanoparticles, it is important to get valid information about the morphology (real 
shape and its surface) of a particle fraction. Thus, a direct visualization via SEM, for 
instance, is necessary. Here, SPM or AFM measurements were additionally 
performed to observe gradual aggregation trends of the nanoparticles in different 
media at various pH values (without necessary purification steps). 
 
Scanning electron microscopy (SEM) 
As residual amounts of additives may prevent an appropriate imaging of the particles 
the NP suspension need to be removed from excess PVOH. Therefore, the 
suspension was treated as described in chapter 2.3.2 method A. 
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Sample preparation: A double-sided adhesive carbon tape was glued onto an 
aluminum stub. A drop (~ 1 µL) of the purified and diluted (1:1,000 with Milli-Q water) 
NPs was pipetted onto a silica wafer and this wafer was placed on top of the carbon 
tape. The particles were dried for at least 2 h at RT and were sputtered with a thin 
gold layer using a Quorum Q150R ES (Quorum Technologies, UK), a compact 
rotary-pumped combined sputter coater and SEM carbon coater (gold coating profile 
‘QT Timed Gold’). The sample was analyzed in a scanning electron microscope JSM 
7001F Field Emission SEM (Jeol, Japan) using the control program “SmartSEM” from 
Zeiss, Germany. 
 
Scanning probe microscopy (SPM) 
With the help of an atomic force microscope (MultiMode AFM from Bruker, USA) the 
NP suspension could be analyzed without any additional treatment (e.g. purification); 
the liquid sample was solely pipetted onto a mica lamella and imaged at tapping 
mode (intermittent contact mode) for a quick visualization of the effect of different pH 
values in water, KRB buffer or PBS buffer on PLGA-Cs NPs. 
 
2.4 Results and discussion 
2.4.1 Preparation technique 
At the beginning, a well established particulate system of chitosan-coated PLGA-NPs 
(1st generation formulation) was used to decide on a preferred preparation technique, 
which can be borrowed for 2nd generation formulations (see chapter 3). Significant 
differences at important preparation steps could be observed by comparing the 
following parameters: 
 
a) dropping methods: Pasteur pipette (manual), peristaltic pump 
(semi-automatic) and syringe pump (automatic) at two different injection rates 
(Figure 2.11) 
b) homogenization speed (rpm) and time (min) (Figure 2.12) 
c) content of Chitosan (Figure 2.13) 
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Figure 2.11 Comparison of different dropping methods from the solvent to the aqueous phase and 
their impact on size and size distribution. Manual method using a Pasteur pipette, semi-automatic 
method via a peristaltic pump (each 150 - 170 µL/min) and an automatic method via a syringe pump 
(100 µL/min and 160 µL/min). [Homogenization: 15,000 rpm, 10 Min.; 15 mg chitosan/100 mg PLGA]. 
As a starting point, the effect of different dropping methods was analyzed. All other 
parameters were maintained as described in Nafee et al. [100]. All three observed 
methods to join the aqueous and solvent phase are suitable for a proper nanoparticle 
production. The automatic (both injection rates, see below) and semi-automatic 
manner (142.9 ± 0.8 nm; PdI: 0.082 ± 0.007) showed good results concerning 
particle size around 140 nm. Slight differences could solely be observed concerning 
particle distribution. Here, a slower injection rate resulted in little smaller particles 
(100 µL/min.: 136.1 ± 3.1 nm; 160 µL/min.: 142.6 ± 0.8 nm) with a higher 
PdI (100 µL/min.: 0.126 ± 0.018; 160 µL/min.: 0.095 ± 0.007). Thus, a reduced 
dropping rate seemed to have a higher influence on the particle distribution as the 
size itself. The manual one revealed slightly bigger particles with 155.2 ± 1.3 nm and 
a broader but still acceptable size distribution (PdI 0.149 ± 0.007, < 0.200). As a 
result, all further preparations will be performed via the automatic implementation 
with an injection rate of 160 µL/min. 
Besides the dropping method, the homogenization speed and time was considered. 
A homogenization via sonification with an amplitude of 40 – 60 % created acceptable 
nanoparticles with a mean diameter of ~ 190 nm and a PdI < 0.2. However, in 
contrast to the homogenization via Ultrathurrax the use of a sonification unit offered 
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no benefit. Hereafter two different homogenization rates (15,000 rpm and 17,000 
rpm) and durations (5 min. and 10 min.) were conferred against one another. To 
protect the equipment against excessive attrition a maximum utilization of 17,000 rpm 
for 10 min. was identified. Apparent from Figure 14 the particle size is more 
influenced by the length of time as by the homogenization rate. A homogenization for 
5 min. created relatively large particles (15,000 rpm: 160.7 ± 0.8 nm, PdI: 0.084 ± 
0.014; 17,000 rpm: 157.8 ± 1.0 nm, PdI: 0.084 ± 0.014), thus a homogenization for 
10 min. seems to be necessary. However, both observed variables had no significant 
influence on the PdI with the result that this preparation step only seems to determine 
the absolute particle size but not the quality of the comminution. 
 
Figure 2.12 Impact of homogenization speed (15,000 rpm vs. 17,000 rpm) and homogenization 
duration (5 min. vs. 10 min.) on size and size distribution.               
[Dropping method: automatic (syringe pump) with 160 µL/min; 15 mg chitosan/100 mg PLGA]. 
Following this, the content of the coating material Chitosan was observed by applying 
15 mg and 25 mg Chitosan at a time to 100 mg PLGA. The ambition was to use as 
little cationic material as possible, as much as necessary. 
Here, the combination of 100 mg PLGA and 15 mg Chitosan formed NPs with the 
following characteristics: 142.6 ± 1.6 nm, PdI: 0.094 ± 0.014, 29.1 ± 2.5 mV. A higher 
amount of Chitosan (25 mg) resulted in clearly bigger particles (161.1 ± 0.7 nm, due 
to a thicker Chitosan shell on the PLGA core) with a higher ζ-potential 
(47.9 ± 5.1 mV). 
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Figure 2.13 Impact of chitosan content
[Dropping method: automatic (syringe pump) with 160
The size distribution was just a 
0.005). As a result of the combination of 100 mg PLGA with 15 mg 
appeared as the better option without g
much Chitosan. For the sake of completeness
chitosan-coated NPs (PLGA
mean size of 128.7 ± 1.0 nm, PdI:
of -14.2 ± 1.5 mV. The addition of chitosan results in clearly bigger particles (142.6 ± 
1.6 nm, PdI: 0.094 ± 0.014) with a positive 
of the ζ-potential (from negative to positive v
supports the thesis of an outer chitosan shell. 
Negligible examined preparation modifications
cannula (with an inner diameter
5 %) as an alternative stabilizer (instead of PVOH). Whereas the homogenization 
step needed to be performed in a small (
plastic falcon tube resulted in an inhomogeneous mixture with 
 
NPs imaging via SEM 
An image captured by scanning
the nanoparticulate system by providing direct information about size, shape and size 
distribution. In Figure 2.14 
e basis of chitosan-coated PLGA nanoparticles (1st generation)
 on NPs characteristics: size and PdI (A) 
 µL/min.; homogenization: 15,
little bit affected to a marginal higher PdI
aining too large particles and
, PLGA NPs were compared with 
-Cs; 15 mg Cs/ 100 mg PLGA). Plain PLGA NPs show a 
 0.043 ± 0.025 and a negative 
ζ-potential of 29.1 ± 2.5
alues) and the increased mean size 
 
 were the usage of a 
 of 0.26 mm vs. 0.41 mm) and PEG 1000 (2.
= 25 mL) glass beaker. The usage of a 
excessive
 electron microscopy allowed a proper assessment of 
a micrograph of purified (method A) PLGA
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and ζ-potential (B). 
000 rpm, 10 Min.]. 
 (0.119 ± 
Chitosan 
 applying too 
ζ-potential 
 mV. The change 
smaller syringe 
5 % and 
 frothing.  
-Cs NPs show 
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consistent spherical shape
mean size seems to be in the same scale, but 
DLS measurement. This impression 
hydrodynamic diameter v
attached to a particle is included. Hence
greater than the size estimated by SEM 
Nevertheless, due to time-
the preferred sizing technique for nanoparticulate systems.
Figure 2.14 Image of purified PLGA
NPs preparation in media 
The resulting PLGA-Cs NPs
slightly acidic pH of 5.5 (T
capacity further pH values (acidic, neutral and
6.2 and 10.6. Comparable values of the buffered systems (
identified. In KRB and PBS buffered systems
not be calculated.  
Apparent from Table 1 the pH
stability. This impact can easily be explained by ionizable amine groups of chitosan, 
pKa ~ 6.5 [129], and the relating pH
a higher pH value, fewer ions (here: anions) can attach to the positive surface of the 
NPs and resulted in a decreased 
 chitosan-coated PLGA nanoparticles (1st generation)
d nanoparticles with a smooth surface. The 
a little bit smaller compared with the 
can be explained by the calculation
ia Stokes-Einstein equation, where the solvent layer 
, the hydrodynamic diameter is always 
[128] or other direct imaging techniques. 
 and cost-saving reasons DLS measurement 
 
-Cs NPs captured by SEM. Scale bar = 200 nm.
-suspension (as described in Chapter 2.2.2) showed a 
able 2.1, shaded in gray). Due to the lack of buffering 
 alkaline) could only be adjusted to 3.5, 
pH 4.0, 7.0 and 9.0) were 
 with a pH > 9.0 reliable results could 
 value had a significant influence on the system 
-dependency of the ζ-potential. In this setup with 
ζ-potential. 
 
 
 
33 
projected 
 of the mean 
remains as 
 
 
Chapter 2 - Optimization of the preparation technique on the basis of chitosan
Table 2.1 Overview of PLGA-Cs NPs characteristics in Milli
acidic (3.5 – 4.0), roughly neutral (6.2 
  
Mill -Q water
pH size [nm]
3.5 166.1
5.5 (as produced) 152.4
6.2 164.6
10.6 223.9
  
KRB buffer 
pH size [nm] PdI
4.0 131.2 ± 1.4 0.014 
7.0 135.1 ± 0.4  0.062 
9.0 175.6 ± 10.7 0.344 
As the system is electrostatically stable with a preferably high or low 
(+20 to +40 mV or -20 to -40
results in particle aggregation indicated by the PdI. The particle size itself seemed to 
rise but is just a mean size of single particle
example for this particle aggregation caused by a 
alkaline conditions) of the system
depicted below (Figure 2.15
Figure 2.15 AFM micrograph (height image)
(B). 
 
-coated PLGA nanoparticles (1st generation)
-Q water, KRB buffer and PBS buffe
– 7.0) and alkaline (9.0 -10.6) pH values. 
 
 PdI ζ-potential [mV] 
 ± 2.2 0.155 ± 0.012 43.8 ± 2.3 
 ± 1.2 0.085 ± 0.008 28.4 ± 0.8 
 ± 3.1 0.219 ± 0.010 24.9 ± 0.5 
 ± 4.4 0.295 ± 0.005 1.8 ± 1.1 
  
PBS buffer 
 
ζ-potential 
[mV] size [nm] PdI
± 0.004 14.4 ± 0.8 139.3 ± 2.6 0.097
± 0.018 5.3 ± 0.4 138.1 ± 0.9 0.115
± 0.018 -2.2 ± 1.2 138.0 ± 2.3 0.214
 mV), the presence of values close to zero
s and particle aggregates. 
changing pH (from acidic 
, particles in KRB buffer at pH 4.0 and pH 9.0 were 
). 
 of PLGA-Cs NP in KRB-buffer at pH 4.0 (A) and pH 9.0 
281.7 nm 
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r at 
 
ζ-potential 
[mV] 
 ± 0.021 7.6 ± 0.6 
 ± 0.013 2.9 ± 0.4 
 ± 0.028 -1.6 ± 0.5 
ζ-potential 
 (0 to ±10 mV) 
As a generic 
towards 
 
 
253.2 nm 
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2.4.2 FA- and DiI-labeled NPs
With the resulting standard method 
NPs were prepared. An 
necessary to interpret later experiments with labeled particles accurately.
juxtaposition of the main parameters 
Table 2.2 NPs characterization (s
 
PLGA-Cs NPs 
FA-PLGA-Cs NPs 
DiI-PLGA-Cs NPs 
 
PLGA-Cs NPs, FA-PLGA-Cs
whereas DiI-PLGA-Cs NPs offered a slightly increased deviation from the 
To assign the results from flu
been shown that the flu-la
suspensions were pictured; the different color of the label
Figure 2.16 FA-PLGA-Cs NPs (
(24,000 x g for 15 min.) fluorescent
After spinning down the particles
is not free in the supernatant. T
particles, which especially 
not covalently bound to the PLGA (as with FA, see 
embedded into the PLGA core (
-coated PLGA nanoparticles (1st generation)
 
(see Chapter 2.3.1) flu-labeled and non
observation on possibly different NP 
is listed below (Table 2.2). 
ize, PdI and ζ-potential) of flu- and non-labeled PLGA
size [nm] PdI ζ-potential [mV]
142.6 ± 1.6 0.094 ± 0.014 
147.0 ± 1.8 0.062 ± 0.014 
146.2 ± 1.7 0.126 ± 0.021 
 NPs, and DiI-PLGA-Cs show all very similar values 
-labeled samples to non-labeled ones it has
bel is incorporated in the NPs. In Figure 
s is clearly visible.
  
A, yellow-green), DiI-PLGA-Cs NPs (B, red)
-labeled NPs (C).  
, the color remains at the bottom (particle 
hat implies the presence of the dye in
was relevant for the DiI-labeled particles since the 
Chapter 2.2.3) but dispersed 
see Figure 2.17).  
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-labeled 
characteristics is 
 A 
-Cs NPs 
 
29.1 ± 2.5 
25.8 ± 0.6 
36.2 ± 0.5 
ζ-potential. 
 additionally 
2.16 both NP 
 
 and spun down 
pellet) and 
side the 
dye is 
and 
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Figure 2.17 A highly simplified and enlarged
NPs (middle) and DiI-PLGA-Cs NPs (right) [blue = PLGA; 
DiI]. 
2.4.3 Purification 
In this context, the purification of the particles was me
amounts of PVOH which had
itself may have an impact on
were analyzed after the completed
Table 2.3 NPs characteristics 
[Method A = spin down and wash, method B
 
particles as produced 
method A 
method B 
method C 
 
 
Figure 2.18 Overview of the impact of different purification methods on NP properties. 
[Method A = spin down and wash, method B
As expected, a harsh purification technique
particle diameters and high 
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-coated PLGA nanopart
 sketch of a NP cut through: PLGA-Cs (left), 
orange = Chitosan; green
ant to remove excessive 
 functioned as a stabilizer. As the purification technique 
 the stability of a particulate system NP
 clean-up procedure (Table 2.3 and 
(size, PdI and ζ-potential) depending on purification 
 = VivaSpin® and method C = VivaFlow
size [nm] PdI ζ-
151.9 ± 2.6 0.143 ± 0.008 
354.5 ± 40.9 0.386 ± 0.016 
199.3 ± 1.7 0.229 ± 0.001 
156.8 ± 2.4 0.178 ± 0.005 
 = VivaSpin® and method C = VivaFlow
 (in particular method A) resulted in large
PdI values (equal to aggregation). A dropped 
method A method B method C
icles (1st generation) 
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Figure 2.18). 
technique. 
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from 43.4 ± 0.5 mV to 6.5 ± 0.4 mV implies that even a portion of the Chitosan shell 
was sluiced down. After Method B a slight aggregation was visible, and method C 
showed unchanged particle characteristics.  
A colorimetric quantification [130] of residual and unbound amounts of the stabilizer 
was envisaged but declined due to the lack of accurate determination of the PVOH 
content in all purified NP suspensions. Later studies (see Chapter 5.2.1.2) show the 
insignificance of the presence of PVOH on cell viability in the applied dilutions. 
Consequently, method A was only used if a complete removal of PVA was desired 
(e.g. for SEM images). In all other cases method C was applied to reduced the 
amount of PVA of the entire preparation bath without changing the colloidal 
characteristics of the nanoparticles. 
 
2.4.4 Loading efficiency 
Determining the loading efficiency [ % = 		 
	  		
			 
	   ∗ 100 ] 
or loading capacity [ % = 		 
	  		
			 	  ∗ 100 ] of a DDS the 
quantification of the cargo is one essential step to describe its potential performance. 
The amount of siRNA can easily be determined by indirect UV or fluorescence 
spectroscopy. 
UV measurement 
Following the thesis that all bound siRNA is fixed on the NPs and all unbound siRNA 
remains free in solution, the suspension of loaded PLGA-Cs NPs was centrifuged, 
and the supernatant was analyzed. An absorption spectrum of siRNA in the 
supernatant of PLGA-Cs NPs is imaged in Figure 23 and shows an independent 
absorption maximum of siRNA (nucleic acids) at 260 nm. Nether residual amounts of 
Chitosan nor the stabilizer PVOH seem to disturb this measurement. Additionally, it 
was shown that the absorption correlates with the amount of siRNA linearly (see 
Figure 2.20) at the utilized concentrations. 
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Figure 2.19 UV-spectroscopy: absorption spectrum of siRNA
[20 mg/mL]. 
Figure 2.20 Linearity of the absorption in a concentration range between 2.5 and 40 µg/m
the supernatant of PLGA-Cs NPs.
After the execution of these preliminary tests the quantification resulted in a 
%LE = 84.3 ± 0.5 % or a %LC
siRNA loading 1:100 = 20
indicates this method as valid.
 
Fluorescence measurement
A quantification via fluorescence spectroscopy requires
fluorescent dye (e.g. SYBR
the observed system allowed
siRNA concentration in the desired concentration range. 
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Figure 2.21 shows increased signal intensity when the flu
PLGA-Cs NPs are brought together, but on the other hand
general provides very low values. 
Figure 2.21 Fluorometric quantificati
(with SYBR® Green II); striped bars = unstained samples.
Figure 2.22 PAGE with 15 %-TBE Gel; inversed image. 1 = PLGA
NPs:siRNA 100:1; 3 = PLGA-Cs NPs; 4 = native PLGA
green II RNA gel stain [1:1,000]. 
The inadequate quantification by fluorescence spectroscopy
unspecific binding between dye
(see Figure 2.22) and a quenching effect of 
quantification of bound siRNA by the fluorescent signal is not indicated for this DDS.
 
2.5 Conclusion 
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generation formulations by using different cationic coating materials. Preparation in 
physiological PBS- and KRB buffer revealed a robust system against the presence of 
various ions and buffer substances. Here, the particle stability was mainly limited by 
high pH values. Above pH 7.0 the formally positive ζ-potential dropped to values 
around zero and caused a loss in stability towards aggregation. 
The Emulsion-diffusion-evaporation technique functions as a resulting standard 
method to prepare flu-labeled and non-labeled NPs. Minor deviations in size and 
ζ-potential between labeled and non-labeled could be observed but do not limit any 
later applications of the samples. Hereafter, FA-PLGA NPs were primarily used 
compared with DiI-PLGA NPs because that the fluorescein amine was covalently 
coupled to the carboxyl group of the PLGA polymer and not only dispersed in the 
PLGA matrix. 
A loading procedure of NPs with siRNA during the preparation step was tested but 
failed due to aggregation tendencies. This might be explained by the additional 
creation of polyplexes between siRNA and free solved chitosan. Furthermore, a 
possible contact of siRNA with organic solvents (here: ethyl acetate) may limit the 
cargo stability. Therefore, a post-loading technique resulted as a simple and safe 
method to bind siRNA on the NPs surface. A suitable quantification of bound siRNA 
could be achieved by an indirect UV-measurement at 260 nm. Resulting LE of ~84 % 
arises as a good starting point for later therapeutic applications. Fluorescent 
measurements show no benefit since blank PLGA-Cs NPs seem to interact 
unspecifically with fluorescent dyes, and bound siRNA showed minor fluorescent 
signals due to quenching effects. 
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Chapter 3 - Suitable coating materials for transfecting 
PLGA-based nanoparticles (2nd generation) 
 
 
 
 
 
 
 
 
 
 
 
 
The author of this thesis made the following contribution to this chapter: 
Planed and performed all experiments related to characterization of coating materials 
as well as particle preparation and characterization, analyzed all the data from the 
mentioned studies, interpreted all experimental data and wrote the chapter, it not 
stated otherwise.  
Julia Müller, who did an internship at the institute and who was instructed by the 
author of the thesis, contributed by this chapter by performing some nanoparticle 
tracking analyzes. 
Fluorescence correlation spectroscopy was performed by George Dandekar at Ghent 
University. He analyzed the data from the mentioned studies and interpreted the 
experimental data. 
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3.1 Introduction 
Gene therapy is the therapeutic insertion of DNA- or RNA-based nucleic acids (NA) 
into a specific cell. For the intracellular delivery of different tools for down regulation 
of expressed genes (e.g. siRNA) or to insert new genes (e.g. plasmid DNA for 
transient expression vectors or carriers are needed. Hereafter, different transfection 
methods can be applied. Table 3.1 shows an overview of transfection reagents and 
methods. 
Table 3.1 Overview of different reagents and methods for transfection. 
Method Reagent/Vector Transfection 
chemical or Calcium phosphate stable/transient 
carrier-based Cationic lipids transient 
Cationic polymers transient 
Dendrimers transient 
DEAE-dextran transient 
Magnetic beads transient 
physical or Micro-injection stable 
instrument-based Biolistic particle delivery transient 
Laserfection stable/transient 
Electroporation transient 
biological or Retrovirus stable 
virus-based Lentivirus stable 
Adenovirus transient 
Adenoassociated virus stable 
Herpes simplex virus transient 
  Vacciniavirus transient 
 
The oldest chemical method represents the usage of calcium phosphate [131]. DNA 
mixed with calcium chloride (CaCl2) in HEPES-buffered saline/phosphate solution 
creates a precipitate which can be taken up by phagocytosis/endocytosis. This 
inexpensive reagent is suitable and efficient for many cell types, however an 
application within RPMI medium (e.g. used to cultivate A549 cells) is not feasible. 
Because of the high concentration of phosphate a precipitation is impossible. 
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Moreover, this method suffers from inefficiency by slight pH changes, a limited 
reproducibility (due to the consistency of the reagent) and relatively high amounts of 
required DNA. Nowadays, a major use of cationic lipids (incl. liposomes [132] and 
lipoplexes) and polymers (e.g. PEI [133], dendrimers [134], Diethyaminoethyl 
(DEAE)-dextran [135]) can be explained by the easy handling and the possibility to 
perform high-throughput systems. Here, conjunctions are created by electrostatic 
interactions of the negatively charged backbone of NAs (phosphate groups) and the 
positive part of a lipid or polymer. However, they are not equally efficient for all cell 
types and can cause toxic effects on cells when applied in high concentrations. A 
relatively new method is a magnet-mediated transfection [136-138]. NAs were 
associated to magnetic NPs (mostly magnetite). When applying a magnetic force, 
this complex is driven into adherent or fixed target cells. This technique benefits from 
a gentle treatment which causes less cytotoxicity and the possibility to perform 
experiments in the presence of serum. 
A frequently used physical based transfection method is the Electroporation [139-
141]. Transient membrane pores will be created by short electrical pulses; plus, small 
particles can pass. Electroporation, in general, is a robust and efficient transfection 
method. However, a compromise between efficiency and viability needs to be found, 
as a high efficiency causes higher cell mortality. Other instrument-based transfection 
methods like biolistic particle delivery [142] (also known as particle bombardment) via 
gene gun [143], laserfection (= opto-injection/photo-transfection) [144] or 
microinjection [145] play a minor part due to high instrumental costs, a laborious 
experimental setup or lower efficiencies. 
Finally, vectors [146, 147] (e.g. lentivirus for stable transfection [148] and adenovirus 
for transient transfection) for in vitro and in vivo gene delivery need to be mentioned. 
They accomplish the highest efficiency (80-90% in primary cells) amongst all 
methods, but certain drawbacks limit their popularity. Next to a limited insert size of 
~10 kb and biosafety issues (e.g. inflammatory response) this technique itself is 
challenging and laborious. 
As mentioned before, many materials can be presented as potential non-viral vectors 
for gene delivery [149-152]. To draw up a shortlist three different biodegradable and 
biocompatible cationic polymers with promising vector-qualities were used to coat 
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PLGA-NPs, obtain a positive surface charge and thus enable delivery of siRNA 
through cellular membrane into the cytosol. Chitosan (Cs) [110, 153-156] (also see 
Chapter 2), Protamine (Prot) [156, 157] and CatStarch [158] represent the selected 
materials. Here, Cs-coated PLGA NPs (PLGA-Cs) constitutes the 1st generation 
formulation. Protamine-coated PLGA NPs (PLGA-Prot) and starch-coated PLGA-NPs 
with (PLGA-CatSt) belong to the 2nd generation of formulations with a retaining PLGA 
core and different cationic coating materials. 
 
3.2 Materials and methods 
3.2.1 Materials 
For particle preparation Poly(D,L-lactide-co-glycolide) (PLGA, CAS No: 26780-50-7) 
Resomer® RG 752 H from Evonik Industries, Polyvinyl alcolhol (PVOH, 
CAS No: 9002-89-5) Moviol® 4-88 from kuraray, Chitosan (Cs, CAS No: 9012-76-4) 
Protasan®UP CL 113 from Novamatrix (Sandvika, Norway), Protamine sulfate 
(CAS No: 9009-65-8) from Sigma-Aldrich and CatStarch (CatSt; in-house synthesis, 
detailed protocol see 3.2.2) was used. SiRNA was kindly provided from COMPACT 
project partner GlaxoSmithKline, UK. Fluorescein amine isomer I (FA, CAS No: 
3326-34-9) to prepare flu-labeled particles was purchased from Sigma-Aldrich. For 
starch synthesis, partially hydrolyzed potato starch was provided from AVEBE, the 
Netherlands. The MW is ~ 1,300,000 g/mol and the content of amylase is ~33%. 
2,2,6,6-Tetramethyl-1-piperidinyloxy (TEMPO; CAS No: 2564-83-2), 
tetraethylenepentamine (tEpA; CAS No: 112-57-2), 4-(4,6-Dimethoxy-1,3,5-triazin-2-
yl)-4-methyl-morpholinium chloride (DMTMM; CAS No: 3945-69-5) and Sodium 
hypochlorite (NaClO; CAS No: 7681-52-9) were purchased from Sigma-Aldrich, 
Germany. Sodium borohydride (NaBH4; CAS No: 16940-66-2) was purchased from 
Merck. Dialysis tubes Fisherbrand®; regenerated cellulose dialysis tubing 15 m roll; 
nominal MWCO 3,500; Fiat width: 46 mm * vol/cm: 6.74 mL; wall thickness: 28 µm; 
dry cylinder diameter: 29.3 mm (21-152-9, T1 membrane 3500 Dalton MWCO 46 
mm) from Fisher Scientific were used. Phosphotungstic acid hydrate (PTA; 
Tungstophosphoric acid; CAS No: 12501-23-4) from Sigma-Aldrich; was used in a 
1% solution for TEM-staining. 
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For gel electrophoresis high-resolution Agarose (CAS No: 9012-36-6), Ammonium 
persulfate (APS; CAS No: 7727-54-0), Tris as Trizma® base (CAS No: 77-86-1) and 
Ethylenediaminetetraacetic acid (EDTA; CAS No: 60-00-4) from Sigma-Aldrich were 
used. Acrylamide, Rotiphorese® Gel 30 (37.5:1) and Tetramethylethylenediamine 
(TEMED; CAS No: 110-18-9) were purchased from Carl Roth GmbH + Co. KG. Gene 
Ruler Ultra Low Range DNA ladder, ready-to-use solution and DNA Loading Dye (6x) 
were bought from Thermo Scientific, Nuclease-free water was provided by Ambion 
by Thermo Scientific. Moreover, the following substances were purchased: boric acid 
(CAS No: 10043-35-3) from Merck Millipore, Germany; DNA LoBind Eppendorf 
Tubes® 1.5 mL, PCR clean from Eppendorf AG, Germany. 
 All other solvents, chemicals, and materials were of analytical grade and are 
designated in the related sections of this chapter. 
 
3.2.2 Characterization of coating materials 
3.2.2.1 Synthesis of a cationic starch derivative 
Maintaining high transfection efficiencies an ideal vector for gene delivery keeps the 
viability of a treated cellular system. Regarding this Yamada et al. confirmed the 
benefit of some synthesized cationic starch derivatives [158] compared to utilized 
positive controls (e.g. jetPRIME). Hence, the coupling reaction of a biodegradable 
starch backbone with cationic side chains was transferred for coating (see 
chapter 3.1) PLGA NPs with this material. 
Starch, in general, is a polysaccharide consisting of linear and helical amylose and a 
branched amylopectin. Biomaterials usually show a high individual variability. 
Therefore it is important to use a material with known and defined characterization 
parameters. For the synthesis of a cationic starch derivate, the starting material is a 
partially hydrolyzed potato starch. The entire synthesis consists of two steps: at first 
the oxidation of the starch to create a water soluble intermediate starch derivate (see 
Figure 3.1 A). After fractionation into different MWs and the determination of the 
degree of substitution a second synthesis step includes the conjugation of the 
Chapter 3 
oxidized starch with a short polyethyleneimine (PEI
3.1 B).  
First of all 20 g of dried potato starch were dispersed in 800 m
stirred for at least 1 hour at 95
with 80 mg (= 4 mg/g starch) 2,2,6,6
strict preservation of pH 8.5, 132
(NaClO) was slowly added followed by 8 g Sodium borohydride. 
overnight, the resulting water soluble and anionic starch derivative was divided into 
different fractions regarding
order by ultrafiltration (Vivaflow
GmbH, Germany): 5,000 MWCO, 30,000 MWCO and 100,000 MWCO (5 kDa and 30 
kDa with a Hydrosart membrane and 100 kDa with a Polyether
For washing Milli-Q water was used. The first cycle separated residu
reagent material from starch 
30,000 MWCO created a ‘small’ fraction of 
100,000 MWCO created a ‘
a ‘large’ fraction of > 100,000 Da
Figure 3.1 Full synthesis of starch
A: starch oxidation, B: conjugation reaction with PEI.
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
 = 0.8 kDa) molecule (see Figure 
L 
 °C.  After cooling down to RT the solution was dosed 
-Tetramethyl-1-piperidinyloxy (TEMPO). Under 
 mL of a 12 percent solution of Sodium hypochlorite
 its MW. The fractionation was performed in the following 
®200 filtration units; from Sartorius 
 sulfone membrane). 
- thus, the filtrate was discarded. The second cycle with 
5,000 – 30,000 Da. The last cycle with 
medium‘ fraction of 30,000 – 100,000 Da 
 (retentate). 
-graft-PEI polymers according to Yamada et al. 
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Milli-Q water and 
 
After stirring 
Stedim Biotech 
al amounts of 
(permeate) and 
 
[158].                       
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To receive oxidized starch as a dry material the separated solutions were 
concentrated with a rotary evaporator (Rotavapor R-215 from Büchi, Switzerland) 
followed by lyophilization (Alpha 2-4, Martin Christ GmbH, Osterode, Germany). 
As the starch with the high MW backbone (AnStarch) was expected to be the most 
promising derivative, it was applied as starting material for the following coupling 
reaction according to Kunishima et al. [159]. The degree of substitution (by sodium 
carboxylate = DSCOONa) was conducted via Blumenkrantz-assay [160], a colorimetric 
method which detects the content of uronic acid, following this equation:  
  ! "#$"%&%#%& ' (%] =  

)×  × 1,000,000
,
AnStarch &' 50 μ7  × 100 
A = absorbance; ε = extinction coefficient 
26 700 lmol-1cm-1, d = cuvette length 
1 cm; m= mass in mg 
This is essential for the calculation of required amounts of tetraethylenepentamine 
(tEpA) and 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride 
(DMTMM). 500 mg of AnStarch (1.09 mmol NaCOO) were suspended in 10 mL 
Milli-Q water before 40 mL DMSO were added to solve the starch (at least 30 min.). 
The conjugation reagent (1.30 mmol DMTMM) needs to be added to activate the 
sodium carboxylate groups (stirring for 30 – 60 min.). The solution was then 
subsequently added to a mixture of 10 mL Milli-Q water, 40 mL DMSO and tEpA 
(27 mmol PEI) and left stirring for 72 hours. Hereafter, purification via dialysis (3,500 
MWCO) against purified water was necessary. To concentrate the resulting mixture, 
a rotary evaporator (pressure set to 25 mbar, water bath temperature: max. 40 °C) 
was used and accrued precipitates (see Figure 3.2) were separated via centrifugation 
before lyophilization. This water insoluble byproduct is likely to consist of large starch 
conjugates and PEI [161] when a high degree of substitution is measured. Because 
of the steric hindrance of the molecule, the attainable degree of substitution is limited. 
A determination of the average molecular weight of the starch derivative was 
performed by gel permeation chromatography (GPC; HLC-8320 GPC, Tosoh, Japan) 
with an online viscometer (ETA-2010, PSS, Germany) in 1 % formic acid (1 mL/min 
at 35 °C) on SUPREMA-MAX 1000 and SUPREMA-MAX 30 columns (PSS, 
Germany). 
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Figure 3.2 Resulting mixture of solved CatStarch and water-insoluble white precipitates of starch 
conjugate and PEI (byproduct) after extensive dialysis against purified water. 
Universal calibration was executed with PSS Poly(2-vinylpyridine) standards 
(Mp 839 – 256,000 Da). Unfortunately, the evaluation was not feasible due to an 
irreparable malfunction of the device. The success of the coupling reaction with 
polyethyleneimine (see Figure 3.1 B) was confirmed by 1H-NMR on a Bruker Biospin 
spectrometer NMR Magnet System 400 MHz Ultrashield plus (Bruker, USA) in D2O; 
δH CatStarch: (1H, 5.20 – 5.60), (2H,3H,4H,5H,6H, 3.30 – 4.22), PEI: (NH-CH2-CH2 
2.48 – 3.28 ppm) and FT-IR measurements in solid state with a Spectrum 400 FT-
IR/FT-NIR spectrometer (PerkinElmer, UK) between 650 and 4,000 cm-1 of the 
synthesized material. 
 
3.2.3.2 Buffering capacity of coating materials 
Once nanoparticles are engulfed into endosomes/lysosomes via endocytosis (see 
Chapter 7.1) the delivery system needs to escape from degrading vesicles. Although 
partially controversial discussed the ‘proton sponge’ hypothesis [162] seems to be 
one meaningful explanation how a delivery system can reach its target compartment 
(e.g. cytosol).  Having an entrapped substance that can neutralize the proton influx 
(e.g. cationic polyplex) causes actively relocated protons (by proton 
pumps = membrane bound H+-ATPase) into the endosome to lower pH. 
Consequently, the substance become protonated (buffering effect) and more protons 
are pumped into, followed by a passive entry of chloride ions (see Figure 3.4 B). Due 
to the increasing ionic concentration an influx of water starts and the vesicle is 
Chapter 3 - Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation) 
 
 
49 
swelling up. Finally, the resulting osmotic pressure causes a rupture (see Figure 3.4 
C) of the endosome and releases the inward into the cytosol.  
As a strong buffering effect of a polymer lead to a fast endosomal escape an acidic 
titration [163] of the different coating materials helped to determine its buffering 
capacity (here: endosome buffering in a pH range between 7.4 and 5.1). For this 
purpose 10 mg of Protamine, Chitosan or CatStarch were dissolved in 10 mL 0.1 M 
NaCl and adjusted with 1 M NaOH to pH 11. The resulting solution was gradually 
titrated from pH 11 to pH 3 with 0.1 M HCl. Endosome buffering capacity was 
calculated as the percentage of amine groups becoming protonated within pH 7.4 – 
5.1 according to the following equation: 
K#!!&' LMNML&%O (%] = ∆QRST ∗ 0.1 VW, 7 ∗ 100 
∆HCl = volume of 0.1 M HCl in µL to decrease the pH from 7.4 to 5.1 
Nmol = total moles of protonable amine groups in 10 mg sample 
 
 
Figure 3.4 Endosomal escape of non-viral gene delivery vehicles (proton sponge hypothesis: pH 
buffering effect). A: entrapment in endosome, B: translocation of protons into the endosome to lower 
the pH, protonation of polymer (resistance against acidifi-cation), C: passive entry of chloride ions 
followed by water influx due to increased ionic concentration, swelling and rupture; adopted from Liang 
et al. [164]. 
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3.2.3.3 Test of endotoxins in raw materials and NP 
suspensions 
To confirm the validity of immunogenicity studies (see Chapter 5.3) an ELISA-based 
Endotoxin Detection Assay (EndoLISA® from hyglos GmbH, Germany) was used to 
exclude a potential immunogenic reaction due to endotoxin contamination. The assay 
was performed as recommended by the manufacturer. Protamine, Chitosan and 
CatStarch as raw materials were solved in endotoxin-free water to a final 
concentration of 1 mg/mL, respectively. A similar procedure was performed with 
PLGA and FA-PLGA and coated PLGA and FA-PLGA NPs but due to the lack of 
water solubility of PLGA the samples could only be dispersed in endotoxin-free 
water. A freshly prepared LPS (500 EU/mL) solution was diluted to create a standard 
curve containing: 0.05 EU/mL, 0.5 EU/mL, 5 EU/mL, 50 EU/mL and 500 EU/mL.  
All samples were examined in duplicates. 
 
3.2.3 Characterization of coated PLGA NPs 
3.2.3.1 NP preparation 
In chapter 2.2.2 the preparation procedure for PLGA-Chitosan-NPs was described. 
For the additional manufacture of PLGA-Protamine and PLGA-CatStarch NPs as 
2nd generation formulations, the same modification of the emulsion-diffusion-
evaporation technique was applied. PLGA (20 mg/mL) dissolved in ethyl acetate was 
slowly added to an aqueous solution of Protamine, Chitosan or CatStarch (3 mg/mL) 
in 2.5 % (w/w) PVOH and homogenized via ultra-turrax. The subsequent addition of 
water increased the amount of the aqueous phase and allowed the ethyl acetate to 
dissolve in water. This migration caused a hardening of the particles and the organic 
solvent was evaporated over night. As the cationic polymers were soluble in water, 
molecules could attach to the anionic surface of PLGA and created coated PLGA  
NPs. The yield or NP concentration in suspension was calculated by the mass of the 
pellet (nanoparticles) after centrifugation of a defined sample volume. 
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3.2.3.2 Colloidal characteristics of NPs 
Photon correlation spectroscopy (PCS) was applied to analyze particle size. 
Zetasizer Nano Series ZSP (Malvern Instruments Inc., UK) was used with the 
following settings. Material: PLGA, RI: 5.500, Absorption: 0.010, dispersant: water, 
viscosity: 0.8872 CP, RI: 1.330, temperature: 25 °C, equilibration time: 120 sec., cell 
type: DTS 0012 disposable sizing cuvette, measurement/scattering angle: 173°, 
backscatter (NIBS default). Dilution: 1:10 diluted with Milli-Q water. Cumulants 
analysis was applied according to ISO13321 (1996) and ISO22412 (2008). 
Results from the nanoparticle tracking analysis (NTA) implemented with the 
NanoSight LM10 (Malvern Instruments Inc., UK) confirmed prior colloidal 
characterizations in specific the size and distribution of the NP suspension. Here, a 
dilution of at least 1:200 was necessary. 
All measurements were performed in triplicates as mean ± SD. Additionally, mode ± 
SD for NTA analysis. 
 
3.2.3.3 Morphology of coated PLGA-NPs (SEM- and TEM-
imaging) 
Scanning electron microscopy (SEM) was conducted as previously described in 
section 2.3.4. For transmission electron microscopy (TEM) a JEOL JEM 2011 
microscope from Oxford Instruments was used. For analyzing NPs loaded with 
flu-labeled ALEXA568-siRNA, no staining protocol was required. All other samples 
(1:10 dilution with MilliQ water) were incubated for 10 min. on a copper grid (‘drop on 
grid’ = dog), stained with a 1% (w/w) PTA solution for 45 sec. (‘grid on drop’ = god) 
and washed with water (god). After the removal of excess fluid with filter paper, the 
samples were dried overnight. 
  
3.2.3.4 ‘Washing’ study 
Chapter 2.4.3 showed a declining ζ-potential (approaching neutral/zero) of PLGA-Cs 
NPs which led to a distinct aggregation tendency. This may be caused by a weak 
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binding of the Chitosan on the PLGA polymer. Implying this, a ‘washing’ study has 
the aim to show how strong the cationic coatings are bound on the surface. Following 
‘method A’ (see Chapter 2.3.2) all coated NP samples were purified and analyzed 
after each stage, totaling three rounds. 
 
3.2.3.5 Quantification and release of bound siRNA 
For determining the loading efficiency of PLGA-Cs NPs (see Chapter 2.4.4) an 
indirect quantification via UV measurement was possible. Since this technique was 
inappropriate for PLGA-Prot and PLGA-CatSt NPs, gel electrophoresis with 10 % 
polyacrylamide or 5 % agarose gel containing 0.5 µg/mL ethidium bromide 
(CAS No:1239-45-8) running with 8V/cm in Tris-borate-EDTA (1xTBE) buffer (89 mM 
Tris (pH 7.6), 89 mM boric acid, 2 mM EDTA) or Tris-acetate-EDTA (1xTAE) buffer 
(40 mM Tris (pH 7.6), 20 mM acetic acid, 1mM EDTA) in) was used to investigate the 
process of siRNA-binding. Per lane 5 µL sample or Ladder mixed with 1 µL 6x 
loading buffer was applied. A release of bound siRNA on the particle surface was 
acquired through the addition of 1 µL heparin (as sodium salt from porcine mucosa 
from Sigma-Aldrich; CAS No: 9041-08-1) diluted in MilliQ water (10 U/µL) to each 
sample. RNA signal was analyzed by UV illuminator Fusion FX7 imaging systems 
from peqlab, Germany. 
Fluorescence correlation spectroscopy is a specific fluorescent microscopy technique 
to measure the release of a particulate system by analyzing a fluctuation profile of 
the fluorescence signal without any physical separation processes. When a 
fluorescent molecule enters the focused spot (= ‘detection volume’) the fluorescent 
intensity increases and drops again when leaving the detection volume. The data of 
FCS analysis (referring to Braeckmans et al. [165]) was generated by George 
Dandekar, Ghent University, COMPACT WP 3 (P11). Stability and release efficacy of 
the DDS was analyzed in HEPES buffer and RPMI medium.  
Samples were loaded with a siRNA-mixture, 1:5 (ALEXA647: GAPDH), by adding 
this solution in a ratio of 1:100 (siRNA: NP) to the nanoparticle suspension. Free 
siRNA-mixture in HEPES buffer measuring the free baseline (see Figure 3.5) and the 
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pure medium to measure the medium baseline were necessary controls for FCS 
analysis since some biological fluids tend to have autofluorescence. 
 
Figure 3.5 Scheme of fluorescence fluctuation profiles of a siRNA solution (free siRNA), a DDS 
dispersion (complexed siRNA) and the surrounded medium to calculate the degree of associated and 
dissociated siRNA. Adopted from Buyens et al. [166]. 
Directly before use loaded NPs were diluted with HEPES buffer or RPMI medium 
(final concentration of fluorescent molecule 5 - 20 nM). The laser beam of an inverted 
microscope (Eclipse TE300 from Nikon, Japan) equipped with a water immersion 
objective lens (Plan Apo 60x, NA 1.2, collar rim correction from Nikon, Japan) was 
focused to 50 µm above a sample containing black glass-bottom 96-well plate from 
Greiner Bio-one, Germany. NIS element software by Nikon allowed the 
implementation of a suitable laser. SymPhoTime by PicoQuant was applied to record 
fluorescent time trace (X-axis: time, Y-axis: fluorescent intensity) for 60 seconds.  
All measurements were conducted in duplicates. 
 
3.3 Results and discussion 
3.3.1 Characterization of pure coating materials 
One main distinction between the described cationic polymers can be made by the 
molecular weight (Mw). As a proper determination of the mean molecular weight via 
GPC was barred due to a persistent malfunction of the system, approximate values 
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from literature or preliminary studies
molecule with 5,100 Da, followed by Chitosan with 
with ~ 61,000 Da [167]) and CatSt with an 
100,000 Da (limitation of smaller molecules due to tang
starch derivative, see Chapter 3.2.2.1). Prior 
Hiroe Yamada, settings for CatStarch
notwithstanding the AnStarch sample was analyzed in 1 M Sodium n
rate of 1 mg/mL at 35 °C on SUPREMA 1000 and 30 columns from PSS, Germany; 
for universal calibration Pullulan, M
resulted in a mean Mw of about
CatStarch polymer [161].  
 
3.3.1.1 Chemical cha
Following the starch synthesis 
resulted in a water-soluble precursor material (AnStarch). The 
hypochlorite controlled the 
of starch modification = 40
fractionation by Blumenkrantz assay
Figure 3.6 1H-NMR spectra of anionic starch (A) and cationic starch (B) derivatives in D
starch, δH AnStarch: (1H, 5.30 ppm
starch with polyethyleneimine (PEI)
ppm – 4.22 ppm), PEI: (NH-CH2-
Based on these value synthesis with the large oxidized intermediate was preceded 
by conjugation of the C6 position of COONa group 
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
 were consulted: Protamine,
50,000-150,000
presumably molecular weight higher
ential flow filt
running GPC analyses (conducted by 
 were used as described in section 3.2.2.1
p 342 – 708,000 Da standards were used
 580,000 g/mol for AnStarch and 830,
racterization of starch derivative
in Chapter 3.2.2.1 the oxidation of the starting material 
amount of sodium 
reaction and defined the degree of modification
 %). The degree of substitution was determined 
 [160] and confirmed a DSCOONa
 – 5.48 ppm), (2H,3H,4H,5H,6H, 3.38 ppm – 4.06
, δH CatStarch: (1H, 5.20 ppm – 5.60 ppm), (2H
CH2 2.48 ppm – 3.28 ppm). 
by the amino groups of PEI. The 
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 as the smallest 
 Da (estimated 
 than 
ration of the 
; 
itrate at a flow-
) 
000 g/mol for 
s 
 (objective 
after 
 of 36 %.  
 
2O, A: oxidized 
 ppm); B: coupled 
,3H,4H,5H,6H, 3.30 
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amount of bound PEI was calculated from 
ratio of 1H of starch (5.20 ppm 
see Figure 3.6 and resulted in a degree of 
approximately 15 %.  
Figure 3.7 IR spectra of starch after oxidation = AnStarch (A
CatStarch (B, blue).  
As FT-IR measurements showed no absorbance of COONa (1604 cm
CatStarch (see Figure 3.7) all COONa groups seemed to be converted. However, the 
calculated result of 1H-NMR was lower than expected. This deviation can be 
explained by the ability of starch and PEI for cross
reactive sites (sodium carboxylate and amino groups). 
 
3.3.1.2 Buffering capacity
A buffering capacity between pH 7.4 and 5.1 (endosomal
power of efficient endosomal escape. Hence, this parameter 
high transfection efficiencies
capacity was evaluated and visualized in
indicates the endosomal pH
5.1 was determined and calculated 
Looking at the titration curve protamine shows a very weak buffering capacity. Only 
25 µL of 0.1 M HCl (∆HCl = 25 µL) were used to cross the endosomal pH range and 
resulted in a buffering capacity of approximately 4 %.
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
1H-NMR results, based on the integration 
– 5.60 ppm) and PEI protons (2.48 ppm 
substitution
, black) and after modification with PEI, 
-linking as both species contain 
 
 
 pH-range) indicates the 
might be responsible for 
. Through an acid-base titration, the endosomal buffering 
 Figure 3.8. Here, the rose colored area 
 range. The required amount of HCl from pH 7.4 t
according to Kim et al. [163]. 
 
 
 
 
55 
– 3.28 ppm), 
 with PEI of 
 
-1) from 
o pH 
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Figure 3.8 Buffering capacity by acidic titration of solved polymer
and CatStarch (green). * indicates
Whereas the two other polymers 
(∆VHCl = 200 µL) seem to have a 
and 5.1. Depending on the req
the pH from 7.4 to 5.1 a calculation of the buffering capacity is possible.
Unfortunately, a proper evaluation
- 12 %) since Chitosan is not soluble 
CatStarch however, suffered from 
Consequently, a calculated 
conceivable and is therefore 
endosomal buffering capacity might be one reason for 
efficiencies. 
 
3.3.1.3 EndoLISA 
As the detection range of this assay ranges from 0.5 EU/m
samples showed a lower content of endotoxins than 0.5
AnStarch revealed a slight endotoxin concentration of 0.15 EU/m
product (CatStarch) of this intermediate derivative contained no endotoxins
results can be neglected. In conclusion, 
NPs cannot be explained by a
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
: Protamine (blue), Chitosan (
 a specific pH value: below pH 6.2 Chitosan is no longer soluble.
Chitosan (∆VHCl = 225* - 400 µL
higher ability to buffer the system
uired amount of hydrogen chloride (
 of this value is not reliable (Buffering capacity:
at a pH lower 6.2. The determination of 
a precise analysis of the molecular weight
buffering capacity between 6 and 34 % might be 
contingent in meaning. Nevertheless,
sufficient transfection 
L to 500 EU/m
 EU/mL with one exception. 
L
a possible immunogenic response of coated 
 contamination with endotoxins (see Chapter 5.2.29
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. As the reaction 
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3.3.2 Characterization of coated PLGA NPs
3.3.2.1 Colloidal characteristics
For the sake of completeness 
non-labeled NPs, were compare
diameter of 130.4 ± 1.3 nm, 
-32.6 ± 0.5 mV. Similar results were obtained for the labeled sample, but with a less 
strong ζ-potential of -21.1 ±
fluorescein which is covalently bound 
Table 3.1 Colloidal characteristics
coated (Prot, CS, CatSt) and non
As fluorescein occupies this functional group
carboxylate. Hence, the surface charge of labeled NPs is 
labeled NPs at a similar size and 
associated increased hydrophobicity 
(from 32.2 ± 0.8 mV to 22.0 ± 
PLGA-Cs NPs since fewer 
PLGA-CatStarch NPs showed a dropped mean diameter 
136.0 ± 1.0 nm) after the 
charge of about 37 mV was 
Table 3.1 Colloidal characteristics of coated NPs in a dil
analysis.  
- Suitable coating materials for transfecting PLGA-based nanopartic
 
 
coated and non-coated NPs, as well as 
d among each. Plain PLGA NPs show a mean size 
a PdI of 0.046 ± 0.005 and a negative 
 0.8. These results can be explained by the presence
to the carboxyl group of the PLGA
 (size, PdI and ζ-potential) of non-labeled and flu
-coated PLGA NPs. 
, it is no longer available to 
less negative
ζ-potential. A less charged PLGA
might also explain the decreased 
0.3 mV) and a slightly varied aerodynamic diameter
amounts of Chitosan bind to the PLGA.
(from 172.3 ± 2.7
insertion of a fluorescent label. However,
retained.  
ution of 1:200 were measured via NTA 
les (2nd generation) 
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flu-labeled and 
ζ-potential of 
 of 
 polymer.  
-labeled (FA) 
 
create a 
 than of non-
-core and an 
ζ-potential 
 of 
 On the contrary, 
 nm to 
 the surface 
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Through steric hindrance the large starch derivative 
associated differently to the PLGA
and resulted in smaller particles
however, were hardly ever affected by the flu
smaller diameter in general
indicated the same trend:  the higher the molecular weight of the coating material
larger the size of the coated NPs
is approximately 10 nm smaller
distribution which is typical for 
homogenization step. In conclusion
NPs, but the calculation is based on the 
values than the ‘real’ state of NPs size.
 
3.3.2.2 SEM- and TEM imaging
Having a look at the morphology of the particles by
results of size measureme
confirmed. Figure 3.9 shows a SEM microgra
expected PLGA-CatStarch NPs are larger than PLGA
larger than PLGA-Prot NPs.
the polymer with the higher
the fact that the outer material of the NPs differs from another, all particles are 
approximately monodisperse and show a spherical shape with
Figure 3.9 Scanning electron micrograph of Protamine
CatStarch-PLGA nanoparticles (C).
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
(see Chapter 3.3.1.1)
-core, thus influenced the thickness of the coating 
. Colloidal characteristics of PLGA
-labeled PLGA. Although showing a 
, the results (mean and mode) of the NTA analysis 
. Differences between mean and mode 
 than mean) indicate a slight ‘tailing’ of the particle 
particle preparation methods 
, DLS is a fast and simple technique to analyze 
hydrodynamic diameter which shows
 
 
 a direct imaging technique
nts (DLS and NTA, see Chapter 3.3.2.1) shall
ph of all three coated PLGA NPs. As
-Cs NPs and these are again 
 Considering the molecular weight of a
 molecular weight creates accordingly lar
 a smooth surface. 
-PLGA (A), Chitosan
 Scale bar: 200 nm. 
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 may be 
-Prot NPs, 
 the 
(mode value 
which include a 
 higher 
, 
 be 
 
 coating material, 
ger NPs. Despite 
 
-PLGA (B) and 
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Additional TEM images were made to indicate differences between flu
siRNA-loaded NPs. Having a look at Figure 3.10 
to visualize PLGA-based NP
created structural artifacts which 
Nevertheless, the particle size c
noticed for PLGA-CatSt NPs followed by PLGA
3.10 A, B, and C).  
Figure 3.10 TEM-micrograph of 
(A/D), Chitosan-coated NPs (B/E) and CatStarch
Phosphotungsic acid. 
Figure 3.11 TEM-images of PLGA
(B). 
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
Phosphotungstic acid
s (low electron density). Unfortunately
impede a statement about the particle shape. 
an be determined, and the largest diameter can be 
-Cs and PLGA-Prot NPs (see Figure 
non-labeled (I) and flu-labeled (II) PLGA NPs: Protamine
-coated NPs (C/F). Negative staining with 1% 
-CatSt (A) and ALEXA568-siRNA loaded (1:100) PLGA
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-labeled and 
 worked well 
, the staining 
 
-coated NPs 
(w/w) 
 
-CatSt NPs 
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Interestingly, only PLGA-CatSt NPs could be depict
procedure (see Figure 3.11) by loading with ALEXA568siRNA in a ratio of 1:100 
(siRNA: NPs). No PLGA-Prot and PLGA
 
3.3.2.3 ‘Washing’ study
Based on privious examinations
their cationic coating due to 
under harsh conditions and analyzed after each washing step. Chitosan
showed the expected behavior of a gradually decreasing 
mV to 1.2 ± 0.4 mV which was explained by a loss of C
surface.  
Table 3.2 Overview of colloidal characteristics of coated PLGA NPs
The almost neutral ζ-potential means a lack of 
the particles (PdI: from 0.125 
Protamine and PLGA-CatStarch NPs showed a different behavior. Protamine
NPs showed an enlarged mean diameter due to aggregation af
second washing step but normalized again after the third one. Merely the surface 
charge remained at a higher level after washing. PLGA
more robust carrier as colloidal characteristics did not change during all p
steps. Reason for that might be a stronger binding of the starch polymer on the 
PLGA. A rationale for the initial aggregation tendency of PLGA
complete dispersal could not be found. Further investigations need to be conduct
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
ed without a prior staining 
-Cs NPs particles could be detected.
 
, where coated PLGA-Chitosan NPs seem to lose 
excessive washing, all three formulations were washed 
ζ-potential 
hitosan on the particle 
 after each washing step
stability and resulted in aggregation of 
± 0.023 to 0.293 ± 0.042). Interestingly, PLGA
-CatStarch NPs seem to be a 
-Prot NPs followed by 
 
 
 
60 
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-
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ter the first and 
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3.3.2.4 Quantification and 
With respect to Chapter 2.4.4
investigated by an indirect UV
transfer this method to determine the amount of bound siRN
and PLGA CatSt NPs failed.
Figure 3.12 Agarose gel (5%) 
siRNA:NPs (1:50), 1 = Ultra Low range 
2 = PLGA-Prot NPs, 3 = PLGA
6 = PLGA-CatSt NPs, 7 = PLGA
ethidium bromide. * band is not visible within this gel
With the help of gel electrophoresi
system was investigated. For this purpose nanoparticle suspensions and the 
corresponding supernatants were applied on a 5 % agarose gel (see Figure 3.12).  
To begin with the employed siRNA 
found slightly above the 20 
marked as an intact sample of 
6) all samples showed a signal inside the agarose poc
on the particle, the applied potential for electrophoresis ha
were too large to penetrate through the gel
point. Merely the PLGA-Cs sample behaved 
one relatively broad band was
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
release 
, the loading efficiency of PLGA-Cs NPs could be 
-measurement of surface-bound siRNA. 
A on of PLGA
  
of loaded NPs and the corresponding supernatant; loading ration 
Ladder (300, 200, 150, 100, 75, 50, 35, 25, 20, 15, 10* bp)
-Prot supernatant, 4 = PLGA-Cs NPs, 5 = PLGA
-CatSt supernatant, 8 = 0.5 µg siRNA, stained with 0.5 µg/m
 
s, the binding behavior of siRNA on the carrier 
contained 21bp. In Figure 3.12 the band could
base pairs (bp) band (line 8: between 20 and 25 bp) and 
nucleic acids. Having a look at the particle
ket. When siRNA 
d no impact
 and the cargo remain
slightly different: The observation that 
 visible between 20 and 25 bp implie
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But trying to 
-Prot NPs 
 
, 
-Cs supernatant, 
L 
 
 be 
s (line 2, 4, 
was bound 
 as particles 
ed at the starting 
d a weak binding 
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behavior of the cargo. Based on the applied potential siRNA was 
particles and pulled into the agarose gel. 
might be possible because of an unspecific binding of ethidium bromide (
Chitosan-coated NPs showed an unspecif
Chapter 2.4.4, Figure 2.22). 
Figure 3.13 TBE gel (1x) of blank NPs, loaded NPs and the
10 U heparine (hep) per sample
200, 150, 100, 75, 50, 35, 25, 20, 15, 10 bp), 2
4 = PLGA-Prot supernatant + hep
7 = PLGA-Cs supernatant + hep
10 = PLGA-CatSt supernatant + hep, 11
13 = Ultra Low range Ladder; stained with 0.5 µg/m
The analysis of the PLGA-
indirect quantification for this particle was feasible. The supernatant of PLGA
and PLGA-CatSt NPs contained no measurable quantities of siRNA. For gel 
electrophoresis, 1 x TBE gels were used to obtain a higher resolution of the bands. 
To see if siRNA was bound on the particle surface, siRNA was released by the 
addition of 10 U heparin per sample (see 
A comparison between line 2 and 12 showed an increased width of the siRNA signal 
(between 20 and 25 bp) after the addition of heparin
these samples (< 15 bp) might be a signal of single
sample. As no siRNA occur
line 3, 6 and 9. Only blank PLGA
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
removed from the 
A minor bold particle signal 
ic binding with fluorescent 
 
 supernatant of loaded NPs
; loading ratio siRNA:NPs (1:50), 1 = Ultra-Low range Ladder (300, 
 = 0.2 µg siRNA, 3 = blank PLGA
, 5 = loaded PLGA-Prot NPs + hep, 6 = blank PLGA
, 8 = loaded PLGA-Cs NPs + hep, 9 = blank PLGA
 = loaded PLGA-CatSt NPs + hep, 12 = 0.
L ethidium bromide. 
Cs supernatant showed a slight siRNA signal, so that an 
Figure 3.13). 
. The second fainter band of 
-stranded molecules within th
red in the blank samples, no bands could be visualized in 
-Cs NPs (line 6) showed an unspecific binding with 
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the ethidium bromide. Line 5, 8 and 11 indicated an almost complete release of the 
siRNA from the coated NPs. The signal intensity of all samples was located in the 
same range compared to the siRNA sample (line 12). Having a look at the 
supernatants of loaded NPs (line 4, 7, 10) PLGA-Prot seem to have bound the 
highest amount of siRNA on the particle surface. Hence, the band of the sample is 
the weakest one. Following this, most unbound siRNA could be found in the 
supernatant of PLGA-CatSt NPs which indicates that less siRNA is bound on PLGA-
CatSt NPs compared to PLGA-Cs NPs and PLGA-Prot NPs. Further investigations 
by another quantification method need to confirm the results of the gel 
electrophoresis. 
Fluorescence correlation spectroscopy was used to analyze the release profile of the 
DDSs in RPMI buffer (see Figure 3.14). In HEPES buffer all loaded carriers were 
stable and showed only a minor release of siRNA only (5 % - 9 %). As PLGA-Cs NPs 
and PLGA-CatSt NPs showed a burst release, which remained stable after 24 hours, 
a time dependent release from ~30 % after 1 hour to ~60 % after 24 hours and 
~70 % after 48 hours at 37 °C was observed for PLGA-Prot NPs. Further 
investigations could be performed via single particle tracking technique to receive 
more information about the particulate system. 
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Figure 3.14 Release profile by FCS analysis of 
NPs in RPMI medium: PLGA-Prot (yellow), PLGA
indicate the release in HEPES buffer as negative control.
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
siRNA-loaded (siRNA:NP ratio = 1:100) 
-Cs (orange), PLGA-CatSt (green); Blue bars 
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PLGA-based 
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3.3.2.5 Bleaching effect
After the preparation of coated FA
obviously different from one another (see Figure 3.15
showed an intense yellow color which 
This observation was less pron
PLGA-Cs NPs. As the flu
(absorption) of the NPs might be accomplished by 
cationic polymers based on interactions with the c
Figure 3.15 Bleaching effect of coated FA
of light exposure (full bleaching). 
 
3.4 Conclusion 
The emulsion-diffusion-evaporation technique to create
applied for the preparation of Protamine
resulting NPs showed suitable colloidal characteristics (particle size < 200 nm, a 
positive surface charge, PdI < 0.2), which were preferable for the uptake of 
nanoparticles. Using the same 
direct comparison of the different formulations. The higher the molecular weight of 
the coating material, the larger the 
shell). In the same order 
lowest ζ-potential of ~ 15 mV
with the highest ζ-potential
coating remains the same, the binding o
the applied material. In this context
- Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation)
 on flu-labeled NPs 
-PLGA NPs, the resulting suspensions appeared 
). Especially PLGA
was fading while increasing light exposure. 
ounced for PLGA-Prot NPs and hardl
-label is only bound on the PLGA a 
a different binding
ovalently bound fluorescein
-PLGA NPs, A: freshly prepared NPs, B: NPs after 2 weeks 
 PLGA-Cs NPs ca
- and CatStarch-coated PLGA NPs. 
amount of cationic polymer, respectively, allows
resulting NPs (probably due to a thicker
surface charges increase from PLGA-Prot NPs with the 
 over PLGA-Cs NPs with ~ 30 mV to PLGA
 of 37 mV.  Although the method for re
f the cationic polymers differs depending on 
, it is possible to wash off certain amounts of 
 
 
 
65 
-CatSt NPs 
y visible for 
diffrent color 
 behavior of the 
. 
 
n be 
All 
 a 
 polymer 
-CatSt NPs 
ceiving a cationic 
Chapter 3 - Suitable coating materials for transfecting PLGA-based nanoparticles (2nd generation) 
 
 
66 
chitosan whereas Protamine and CatStach stay unaffected at the particle surface. 
Merely the rising ζ-potential of PLGA-Prot NPs after the first washing step remains 
undeclared. 
Gel electrophoresis of siRNA-loaded and released (displaced by heparin) siRNA-
loaded particles indicated that high loading efficiencies were not only based on 
possibly high surface charges. The interaction between siRNA and cationic polymer 
seemed to be one further influencing factor. Again a less strong binding of chitosan 
and consequently siRNA could be confirmed, as the electrical potential was able to 
drag the cargo off from the particles. However, PLGA-Prot and PLGA-CatSt NPs and 
the corresponding supernatants showed no siRNA signal. After the release of bound 
siRNA with heparin, all particles released approximately the same amount of applied 
siRNA. Analyzing the released samples of the particle supernatant, PLGA-CatSt NPs 
bound the highest amount of siRNA within the surrounded fluid followed by PLGA-Cs 
NPs and PLGA-Prot NPs. A formation of small siRNA-polyplexes with the available 
cationic polymer might be one possible explanation for the release of siRNA without 
the presence of the PLGA-based DDS. 
Furthermore, a difference in buffering capacity for the three cationic polymers could 
be shown. Considering that gene delivery activity can be referred to a balance 
between the buffering capacity of a polymer (indicating the potential for endosomal 
escape) and the strength of interactions between polymer and nucleic acids [168] the 
transfection efficiency of a system is based on more than one attribute. If these 
differences in buffering capacity can also be seen in an endosomal escape assay, a 
direct correlation might be confirmed.  Nonetheless, transfection studies on different 
lung specific cells are essential to prove the efficiency of a drug delivery system. 
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Chapter 4 - Stability of drug delivery systems for 
pulmonary application 
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Planed and performed all experiments related to particle stability, analyzed all the 
data from the mentioned studies, interpreted all experimental data and wrote the 
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4.1 Introduction 
Since the invention of first metered dose inhaler (MDI) in the 1950s [169] an 
application of drugs via the lung has become a feasible option. By now an inhalation 
therapy with anticholinergics [e.g. Tiotropium bromide (Spiriva®), Ipratropium bromide 
(Atrovent®)] β2-adrenegic agonists [e.g. Fenoterol (Berotec® N), Salbutamol 
(Ventolin™)] or glucocorticoids [e.g. Beclometasone dipropionate (Qvar®)] belong to 
the standard therapeutic recommendation for diseases like COPD or asthma. 
Nevertheless, a successful pulmonary delivery of biomacromolecules (proteins, 
peptides, and nucleic acids; see Chapter 1.1.1) is still pending. 
Depending on the drug or the employed carrier system and the potential patient 
group different inhalation devices may be suitable for a proper pulmonary application. 
Nowadays, four different main groups of therapeutic inhalation devices are available: 
dry powder inhaler (DPI), pressurized metered dose inhaler (MDI), Respimat® and 
nebulizer. DPIs (e.g. Breezhaler®, Diskus®, Easyhaler®, Genuair®, Handihaler®, 
NEXThaler®, Novolizer®, Turbohaler®) are convenient and portable inhalation 
devices. The drug deposition occurs breath-actuated by a fast and deep breath. 
Consequently, less patient coordination is required [170]. However, additional 
excipients (e.g. lactose) are necessary, plus the delivery of high doses is difficult. 
MDIs, by contrast, use a propellant for aerosolization. Thus patient coordination is 
essential (non-breath actuated: simultaneous deep breath and triggering of the 
aerosol formation) and just like DPIs the delivery of high doses is limited. The 
Respimat® established the group of soft mist inhaler (SMI), which enlarges the 
dwelling time of the aerosol and minimizes the failure due to missing patient 
coordination. In general, it is an advanced MDI. With a nebulizer (e.g. Aeroneb® Go, 
eFlow® rapid, I-neb®, AKITA® jet, PARI Boy®) it is possible to inhale high doses 
completely without necessary patient coordination. They are particularly suitable for 
the therapy of children. But these devices are not handy and preferably made for 
domestic use.  
Advanced inhalation devices produce an aerosol with a mean particle or droplet sizes 
of around a few µm to allow an efficient and precise aerosol deposition in the deep 
lungs (= pulmonary) for either topical or systemic delivery. Studies showed that the 
aerodynamic diameter determines the place of deposition in the human respiratory 
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tract [87, 171].  In Figure 4.1 the deposition fraction of inhaled aerosol is plotted 
against particle diameter and respiratory region (head airways, trachea-bronchial and 
pulmonary).  
 
Figure 4.1 Fractional regional deposition of inhaled particles in the human respiratory trakt (Snipes 
1994). Reprinted with permission from Medical Physics Publishing, Madison, Wisconsin.”[171, 172] 
As properties like particle size, the maximum amount of substances, microbial 
stability and storage stability may preclude a certain inhalation device, the focus in 
this chapter is put on the stability of the DDSs during storage, after lyophilization and 
after aerosolization via a nebulization device.  
 
4.2 Materials and methods  
 Trehalose dihydrate (α,α-Trehalose; CAS No: 6138-23-4) was purchased from 
Sigma-Aldrich, USA; Ribonuclease A (RNase A) 17500U, 2.5 mL from Qiagen. 
Purified water was produced by Milli-Q water purification system from Merck 
Millipore, USA. 
Colloidal characteristics of all NP suspensions before and after nebulization were 
measured concerning the described method in Chapter 2.3.1. and were conducted in 
triplicates. 
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4.2.1 Storage stability 
For later applications, this carrier system needs possibly long storage stability due to 
the required post-loading mechanism. If a particulate carrier is not sufficiently stable 
for storage, this may limit the application of a whole DDS. In our case, the cargo can 
be stored separately freeze-dried apart from the carrier system and can be used 
directly before the loading step. Thus, a possible loss of cargo activity is limited. To 
investigate the storage stability of the particles at different storage conditions (4 °C, 
RT and 37 °C), prepared NPs suspension in a concentration of 2 mg/mL were 
observed. Samples were measured at different times up to 35 days (5 weeks). To 
ensure that variances are solely based on the storage temperature, samples were 
protected and sealed against light exposure, inadvertently shaking and 
contaminations. 
 
4.2.2 Freeze dried NPs 
As we know that PLGA-based NPs are not suitable to be stored at -20 °C (creation of 
solid aggregates), NP suspensions were freeze-dried (Alpha 2-4, Martin Christ 
GmbH, Germany) overnight with different amounts of trehalose as cryoprotectant to 
obtain a possible storage of the NPs as a dry powder. After lyophilization, an 
adequate amount of Milli-Q purified water was added to obtain the native sample 
concentration of redispersed particles. Particle characteristics were determined 
approximately 15 min. after water addition.  
 
4.2.3 Nebulization 
As the stability of a DDS after nebulization is mainly dependent on the applied 
nebulization method, three different devices were investigated. Here, one device for 
in-vitro, in-vivo and a therapeutic application was selected respectively. The 
Aeroneb® Lab Nebulizer from Aerogen (Figure 4.2) was chosen for its ability to 
deposit a defined volume of the DDS directly on an in-vitro cell culture model 
(nebulizer unit fits on a 12-well cell culture plate). An OnQ® Aerosol Generator 
creates a low-velocity aerosol with fine droplets by imbibing the liquid through a 
 vibrating (micro pumping action) 
small volumetric mean diameter (VMD)
and 4.0 µm, a flow rate > 0.1 m
(values taken from the instruction manual)
filtered (Minisart® Syringe filter 0.2 µm from 
Germany) prior to usage, filtered and filtered+nebulized samples were measured. 
total volume of 2 mL of 
nebulized, and the resulting mist was collected with the help of a 5
(from greiner bio-one GmbH, Germany)
Figure 4.2 Aeroneb® Lab Micropump Nebulizer
Volumetric Mean Diameter (VMD = 
The second considered device 
Figure XA). Within COMPACT 
University of Vienna) were plan
deviations in size and surface charge 
liquid (25 - 250 µL) is forced out air
passageways and emerges as a fine mist at the very tip (inner diameter: 60 µm). This 
device is assigned for intratracheal (intrapulmonary) liquid application in mi
Figure 4.3 B) and creates droplets with a mass mean diameter (MMD) between 
16 and 22 µm. Again unfiltered, filtered
Millipore) and filtered + nebuli
Here, the total syringe volume of 250 µ
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domed aperture plate with precise holes
 nebulizer unit with a particle size
L/min and a residual volume > 0.2 m
. As samples for in-vitro testing need to be 
Sartorius Stedim Biotech GmbH, 
each NP suspension (concentration: 2 mg/m
. 
 
 (A) from Aerogen (www.aerogen.com)
2.5 – 4.0 µm) Nebulizer Unit (B), OnQ® Aerosol Generator (C).
was the MicroSprayer® from Penn
in-vivo studies (in cooperation with our
ned as long as the DDS show
after nebulization. To create an aerosol
-free (with a high-pressure syringe) through the 
 (Steriflip®-GP filter unit 0.22 µm from 
zed samples (concentration: 2 mg/mL
L was nebulized and collected in
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. Here, the 
 between 2.5 
L was used 
A 
L) was 
0 mL falcon tube 
, Small 
 
-Century (see 
 partner (P8) at 
ed no significant 
, the 
ce (see 
Merck, 
) were measured. 
to 15 mL 
 falcon tubes (from greiner bio
until a total volume of 2 mL 
Figure 4.3 MicroSprayer® (215) 753
Aerolizer) from Penn-Century (www.penncentury.com
application in mice (B). 
An established inhalation device for the therapeutic 
physiologic saline solution in humans
fibrosis/mucoviscidosis) is the eFlow
(see Figure 4.4). Referred to the technical data sheet a volume between 2.0 and 
6.0 mL is converted into an aerosol with 
membrane (aerosol head 30;
respiratory tract. 
Figure 4.4 eFlow® rapid nebulizer system (A) from PARI (
Aerosol heads with different perforated membranes
describe the size of membrane perforations in µm) could be investigated. Acc
to the manufacturer, the commercial
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-one GmbH, Germany). This procedure was repeated 
was accrued. 
-6540 (FMJ-250 High Pressure syringe; Model IA
); MicroSprayer® aerosol cloud (A) and in
application 
 (e.g. for a patient with cys
®
 rapid nebulizer from PARI GmbH, Germany
a MMD of 4.1 µm via a perforated oscillating 
 oscillating frequency: 117 kHz) to reach the lower 
www.pari.com), aerosol head (B).
 (20, 30, 35 and 45; numbers 
ly available eFlow® rapid contains a 30
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aerosol head solely. Again 2 mL-samples (concentration: 2 mg/mL) were nebulized 
and collected into 50 mL falcon tubes (from greiner bio-one GmbH, Germany). Here, 
the same initial NP samples were used for stability studies with the Aeroneb® Lab 
and eFlow® rapid device. 
 
4.3 Results and discussion 
4.3.1 NPs stability at 4 °C, RT and 37 °C 
Coated PLGA NPs were stored in suspension at 4 °C, RT, and 37 °C to investigate 
how far the coating material and thus the particle size and ζ-potential is affected by 
different storage conditions over time. Figure 4.5 shows changes in both parameters 
over a 35 day period after preparation. Comparing storage conditions at 4 °C and RT 
no significant changes in size or ζ-potential apart from the PLGA-Chitosan sample 
which shows a reduced ζ-potential from 25.7 ± 0.4 mV (day 28) to 17.8 ± 1.0 mV 
after 35 days could be revealed. Merely an enduring storage temperature of 37 °C 
has a coherent influence on particle stability. After 5 weeks a reduced surface charge 
could be noticed for all coated NPs: PLGA-Prot NPs from 13.8 ± 0.1 nm (day 1) to 
8.1 ± 0.5 nm (day 35); PLGA-Cs NPs from 27.2 ± 0.2 nm (day 1) to 16.3 ± 3.7 nm 
(day 35); PLGA-CatStarch NPs from 37.2 ± 0.3 nm (day 1) to 26.8 ± 0.1 nm (day 35). 
Moreover, the hydrodynamic diameter of all three coated particle samples was 
decreased: PLGA-Prot NPs from 125.1 ± 0.6 nm (day 1) to 110.2 ± 0.3 nm (day 35); 
PLGA-Cs NPs from 141.5 ± 0.9 nm (day 1) to 111.8 ± 0.9 nm (day 35); PLGA-CatSt 
NPs from 163.8 ± 1.7 nm (day 1) to 147.2 ± 1.6 nm (day 35).  
Noticeably, PLGA-Prot and PLGA-Cs NPs showed a similar particle size after 35 
days. As uncoated PLGA NPs have a diameter of around 130 nm (see chapter 3.3.2) 
and the surface charge of these particles is still positive after 5 weeks, the reduced 
size of the coated NPs can not only be explained by a degraded coating. The 
presence of a sheer inner PLGA core covered with a gradually increasing 
concentration of the cationic material PLGA and PVOH (outer shell) seems to be 
likely.   
 
 Figure 4.5 Storage stability: changes in size 
4° C (A/B), RT (C/D) and 37 °C (E/F) 
Cs NPs, green = PLGA-CatSt NPs.
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(A/C/E) and ζ-potential (B/D/F) of coated PLGA NPs at 
over a 35 days’ period. Blue = PLGA-Prot NPs
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, yellow = PLGA-
 Figure 4.6 shows a SEM micrograph of coated PLGA NPs after preparation 
and after 6 weeks at 37 °C
appeared vague, less smooth
resulted probably due to the sample preparation. The washing step to get rid 
PVOH seemed to affect the stored particles more than the fresh
Figure 4.6 SEM micrographs of
37 °C (II): PLGA-Prot NPs (A/D), PLGA
 
4.3.2 Re-dispersibility 
To investigate whether freeze
PLGA NPs were analyzed. Here, different amounts
taken into consideration and the 
boxes (see Table 4.1). 
cryoprotectant is not mandatory
coated NP from -22.5 ± 0.6 mV to 
when a little trehalose is present. For PLGA
(w/w) trehalose is needed to prevent aggregation
and a PdI of 0.052 ± 0.012 to 149.0
problematic to freeze-dry and re
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 (II: D/E/F). After storage, the surface of the
 and a little bit smaller. The reduced amount of particles 
ly prepared ones.
 coated PLGA NPs as produced (I) and after storage for 
-Cs NPs (B/E) and PLGA-CatSt NPs (C/F).
after lyophilization 
-drying affected NP characteristics native and coated 
 of trehalose (up to 1.0%) 
most favorable combination was marked by colored 
For PLGA and PLGA-CatSt NPs an addition of a 
. Merely an increased negative ζ-
-35.7 ± 1.7 mV could be observed, but normalize
-Prot NP a minimum amount of 0.2% 
 of the NPs from 122.3 
 ± 1.2 nm a PdI of 0.182 ± 
-disperse PLGA-Cs NPs. Even with 1.0% (w/w) 
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(I: A/B/C) 
 particles 
of 
 
 
6 weeks at 
 Scale bar: 200 nm. 
were 
potential of non-
d 
± 1.2 nm 
0.008. It is more 
 trehalose an increased mean particle size could admittedly be revised but not 
completely prevented.  
Table 4.1 Properties of different NPs after lyophili
frames mark the minimum quantity of trehalose 
blue = PLGA-Prot NPs; orange =
Furthermore, the lyophilization process itself seems to change the surface charge 
from 24.4 ± 0.5 mV for freshly prepared NPs to 51.2 
cryoprotectant. Anyhow, the more trehalose is added
ζ-potential are brought closer to the results
 
4.3.3 Stability after n
For later transfection studies on cell culture models under ALI 
conditions NP stability after nebulization with
Table 4.2). Beforehand a
(surfactant-free) membrane did not affect a single one of the NP suspensions. This
filterability indicates an adequate
2.2.2 and 3.2.3) without forming bigger polymer aggregates.
PLGA-CatSt NPs did not change and retained prior particle characteristics. Whereas 
PLGA-Prot NPs apparently aggregate from a mean diameter of 124.6 nm 
158.1 nm ± 0.7 nm and a PdI from 0.049 
additionally showed an increased 
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zation and re-dispersion with Milli
in %(w/w) as cryoprotectant [
 PLGA-Cs NPs; green = PLGA-CatSt NPs]. 
± 0.5 mV for tre
, the more values for 
 of untreated NPs.  
ebulization 
(air
 the Aeroneb® Lab was investigated
 filtration step through a 0.2 µm cellulose acetate 
 and complete preparation procedure (see C
 After atomization, o
± 0.030 to 0.154 ± 0.021, PLGA
ζ-potential from 31.6 ± 0.4 mV to 53.2 
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ated NPs without 
size and 
- liquid interface) 
 (see 
 
hapter 
nly 
± 1.3 nm to 
-Cs NPs 
± 0.5 mV.  
 Table 4.2 Stability: NPs characteristics after nebulization via Aeroneb
happened through a Minisart® syringe filter, 0.2 µm cellulose acetate (CA) membrane.
For later in-vivo applications all coated PLGA NPs and blank PLGA NP seem to be 
suitable as no changes in size or surface ch
Merely the ζ-potential of PLGA
after filtration. This issue can be explained by possibl
the filter membrane. Since the MicroSprayer
applications with a MMDMicroSprayer
2.5 - 4.0 µm and a MMD
Furthermore, the atomization of the MicroSprayer
(see Chapter 4.2.3) and devia
Table 4.3 Stability: NPs characteristics after nebulization via MicroSprayer
happened through a Steriflipt®-GP
Exact results of freshly produced and f
NP batch was used for studies with Aeroneb
bar chart of coated PLGA NP: t
against the utilized aerosol head. As expected t
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®
 Lab device. 
arge could be observed (see Table
-NPs shifted from -31.3 ± 0.8 mV to 
e binding processes of ions onto 
®
 creates bigger droplets for intratracheal 
 of 19 – 22 µm (compared to a VMD
eFlow = 4.1 µm) less distinct variances
®
 was subject to another method 
tions became evident. 
 filtration unit, 0.22 µm polyethersulfone (PES) membrane.
iltrated NPs are displayed in 
® Lab and eFlow®). Figure 4.7
he mean particle size diameter and PdI 
he membrane with the smallest 
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Filtration 
 
 
 4.3). 
-19.3 ± 1.0 mV 
Aeroneb of 
 were expected. 
®
 device. Filtration 
 
 
Table 4.2 (same 
 shows a 
were plotted 
 perforations (‘25’) showed the biggest 
aerosol head PLGA-CatSt NPs remain its initial size and PdI
PdI of ~ 0.040. PLGA-Prot NPs
PdI from ~ 125 nm, PdI ~ 
PLGA-Cs NPs is only acceptable (152.0 
‘45’ aerosol head.  Smaller perforated membranes resulted in NP aggregates
~ 145 nm with a PdI ~ 0.100
change of the ζ-potential was 
Figure 4.7 Comparison of nebulization stability (mean size and size distribution)
head (low number = small droplets) 
(blue), PLGA-Chitosan (green), PLGA
 
4.4 Conclusion 
PLGA NPs were coated with cationic and water
chitosan, and starch). Although 
material on the surface of the delivery system determin
storage of a nanoparticle suspension is limited
processes at 37 °C after two weeks. 
for at least 35 days is feasible 
important aspect thus particle suspensions show (apar
samples) a limited re-dispersibility after lyophilization. Maybe the freeze
process is not optimally designed 
(w/w) trehalose as a bioprotectant
less favorable for chitosan-coated NPs. As chitosan
character [174] this behavior 
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impact on the particles. Nevertheless,
 around 157 nm and a 
, however, showed a remarkable increase
0.050 to 160 – 230 nm, PdI > 0.2). A nebu
± 1.2 nm, PdI: 0.147 ± 0.021) when using a 
. Results of the surface charge were not shown since
apparent. 
 depending on aerosol 
of PARI eFlow® rapid device and particle type. PLGA
-CatStarch (yellow). 
-soluble substances (protamine, 
having the same PLGA basis in the inner cor
es the stability properties.
 due to starting aging or aggregation 
However, retaining the samples at 4
without any concerns. The storage stability
t from CatStarch coated 
for proteins. It is known, that the 
 [173] can prevent aggregation. This treatment was 
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to lyophilization, the structure might be damaged, and a re-dispersion ends up in 
aggregates. 
Nebulizers are preferred devices in line for later therapeutic applications of the 
investigated DDSs. The Aeroneb® Lab and the eFlow® devices use an oscillating 
membrane to create an aerosol. As the atomization technique means a high 
mechanic stress for the particles, it is comprehensible that stability can be affected. 
The use of different aerosolization heads divergent in size of the perforations showed 
a stronger aggregation the smaller the holes in the membrane are. Again, 
CatStarch-coated NPs indicate a better resistance. A more robust  binding of the 
starch derivative on the PLGA particle compared to chitosan or protamine might be 
one explanation. This aspect can be partially substantiated by the washing procedure 
(see Chapter 3.3.3.4): it was possible to wash off amounts of the chitosan coating 
(dropped ζ-potential) due to harsh centrifugation and re-dispersion. A filtration of all 
NP samples through a 0.2 µm filter is viable. Very low (protein) binding membranes 
for aqueous solutions (Minisart®: cellulose acetate and Steriflip®: polyethersulfone) do 
not interfere with the cationic coating of the NPs, and no difference between both 
membrane materials is present. Only the comparison of both membranes with 
uncoated PLGA NPs is not yet confirmed. As the evaporation of ethyl acetate during 
NPs preparation proceeded completely, it is not necessary to take the incompatibility 
of these membranes with the organic solvent (ester) into account. 
Prospective, detailed experiments concerning the cargo stability need to be 
analyzed. The stability of the siRNA, after nebulization of the complete drug delivery 
system (e.g. via gel electrophoresis) followed by transfection studies of aerosolized 
loaded carriers is one idea. The resistance of bound siRNA against degradation 
(RNase A) is another important parameter to investigate. Preliminary studies were 
already conducted and showed certain stability against mechanical stress 
(= nebulization) and resistance against RNase A (see Figure 4.8). But as this data 
results merely from preliminary studies and should be repeated with a high quality 
siRNA (only one visible band) and with additional released samples and different 
loadings to allow a substantiated statement (especially since no signal of siRNA on 
PLGA-Prot NPs could be found). 
 Figure 4.8 TBE gel (1x) of loaded NPs and 
30 min. at 37°C or loaded NPs and 
ratio siRNA:NPs (1:50), 1 = 0.2 µg siRNA + RNase A, 2 = 0.2 µg siRNA, 3 = loaded PLGA
RNase A, 4 = loaded PLGA-Cs NPs + RNase A, 5 = loaded PLGA
6  = Ultra-Low range Ladder (300, 200, 150, 100, 75, 
8 = 0.2 µg siRNA neb., 9 = loaded PLGA
PLGA-Cs NPs, 12 = loaded PLGA
PLGA-CatSt NPs neb; stained with 0.5 µg/mL ethidium bromide.
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The author of this thesis made the following contribution to this chapter: 
Planed, designed and performed all experiments related to cytotoxicity by MTT 
assays and MTS/PMS on THP-1 cells, analyzed all the data from the mentioned 
studies, interpreted all experimental data and wrote the chapter, it not stated 
otherwise. 
Cell culture of hAELVi cells was performed by Stephanie Kletting. 
MTS/PMS assay und ViaLight™ assay were implemented and analyzed by Stine 
Rønholt at University of Copenhagen. 
The immunogenicity studies were performed by Anne Marit de Groot at Utrecht 
University. She analyzed the data from the mentioned studies and interpreted the 
experimental data. 
NF-кB activation assays were performed by Pharmacoidea under the direction of 
Tamás Letoha. He analyzed the data from the mentioned studies and interpreted the 
experimental data. 
 5.1 Introduction 
The preparation of nanoparticle
and more the question concerning
medical applications a prediction of the
formulations is indispensable
as Safe) may be applied as well as the 
for final formulations [176]. Here, a
crucial. Regarding this, Lehr and Groß described a safety 
(modification see Figure 5.1
Figure 5.1 Safety classification
non-nano-forms [178] (adopted and modified from 
Despite these preliminary theoretical 
nanoparticulate systems are
These include, inter alia, the assessment of cytotoxicity and immunogenicity on 
target cells. As the designed nanoparticulate system
intended for pulmonary applications
First, monocultures of epithelial
the upper and lower respiratory tract were evaluated.  For the alveolar region A459 
cells and for the bronchial 
commonly used epithelial cell lines. La
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. A database of GRAS materials (Generally Recognized 
NCS (Nanotoxicology Classification System
 comparison of nano and non-nano 
classi
) for nano-products and materials [177]. 
-system for  nano-products and materials in comparison to their 
Lehr and Groß [177]). 
considerations in vitro evaluation
 essential before getting permission for 
 (see chapter 2
 studies need to include lung specific cell
 lung cells (main barrier for particles to overcome) of 
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[179, 180] or triple-culture [181, 182] may show more reliable results due to a better 
accordance with the conditions in the human body.  
Within this chapter established cell viability and immunogenicity tests were performed 
to receive a first impression about the safety profile of applied formulations and 
DDSs. Although a direct correlation between in-vitro and in-vivo results is limited to 
preliminary studies on cell culture models before going into animals are still 
obligatory. 
 
5.2 Materials and methods 
5.2.1 Cell viability 
Within COMPACT viability studies were implemented by Stine Rønholt (P3, WP3) 
through MTS/PMS assay und ViaLight™ assay. Furthermore, apart from COMPACT, 
MTT assays were performed. 
 
5.2.1.1 Cell culture 
Macrophages 
Human monocyte-derived cell line (THP-1; DSMZ No. ACC 16) [183-185] from an 
acute monocytic leukemia patient were obtained from the Leibnitz-Institute DSMZ-
Deutsche Sammlung von Mikroorganismen und Zellkulturen in Braunschweig and 
cultivated in Roswell Park Memorial Institute (RPMI) 1640 medium (from Gibco by 
Life Technologies, USA) supplemented with 10 % FBS. Cells were applied as 
suspension cells (non-stimulated) and as adherent macrophage-like cells (stimulated, 
see Figure 5.2).  
The differentiation process was implied by the addition of 7.5 ng/mL Phorbol 12-
myristate 13-acetate (PMA; CAS No.: 16561-29-8) [186] followed by 24 h incubation 
under standard cell culture conditions (37 °C with a humidified 95 % atmosphere 
containing 5 % CO2). For viability assessment of adherent cells 1 x 105 cells/well 
were seeded in a 96-well plate; the same amount was used for suspended cells (not 
stimulated). 
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Figure 5.2 THP-1 cells (100,000 cells/well; in 24-well cell culture plate) 24 h after differentiation with 
PMA. Some adherent macrophage-like and spherical suspension cells are visible in parallel. 
Epithelial cells 
Adenocarcinomic human alveolar epithelial cells (A549; ATCC® No. CCL-185™) 
[187] from ‘American Type Culture Collection’ (ATCC) represent AT II-like epithelial 
cells [188, 189] and were cultivated in RPMI 1640 medium + 10% FBS under 
standard conditions (see above). For the MTT assay 10,000 cells/well and for 
MTS/PMS and Vialight assay 9,000 cells/well were seeded in 96-well plates. 
Calu-3 (ATCC® No. HTB-55™) [190], a adenocarcinoma-derived human bronchial 
epithelial cell line was purchased from ‘American Type Culture Collection’ (ATCC). 
Cells were cultivated under standard conditions in Minimum Essential Medium 
(MEM) supplemented with 1% Non-Essential Amino Acids (NEAA: Glycine 750 mg/l, 
L-Alanine 890 mg/l, L-Asparagine 1320 mg/l, L-Aspartic Acid 1320 mg/l, L-Glutamic 
Acid 1470 mg/l, L-Proline 1150 mg/l, L-Serine 1050 mg/l and 1% sodium pyruvate). 
 
5.2.1.2 MTT assay 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is an intracellular  
colorimetric assay [191] to detect the metabolic activity by the amount of NAD(P)H-
dependent cellular oxidoreductase enzyme (only present in living cells). MTT (yellow 
color) is reduced into insoluble (purple color) formazan which is located in the cytosol 
(see Figure 5.3). 
 Figure 5.3 Light microscope: Image of A549 cells (positive control in HBSS) with intracellular purple 
formazan crystals after the treatment with MTT reagent (tetrazole). 
Hence, dimethyl sulfoxide (DMSO) needs to be ad
measure the amount of formazan. 
protocol: A549 cells were se
culture plate and incubated for two days at 37
atmosphere. The medium
pre-warmed (at 37 °C) HBSS
Gibco by Life technologies, USA
filtrated with Steriflip®, 0.22 µm
1.0 mg/mL), 1% TritonX-100 in HBSS
negative control were added and
Afterward the supernatant was remove
Sigma M5655-1g) stock solution (5 mg/m
HBSS and 100 µL were applied on cells for 4 h under gentle shaking and protection 
against light exposure respectively
of 100 µL dimethyl sulfoxide
the dark. The absorption of the resulting colored solution was quantified by 
measuring at 550 nm with Tecan i
follows: 
A: absorption sample, S: absorption 
LD50 values were calculated
Chapter 5 - Cell viab
 
Scale bar 20 µm.
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The assay was performed with 
eded at 10,000 cells per well (0.2 µL) in a 96
 °C, 5 % CO2 
 was removed, and cells were wash
 (pH 7.4, + CaCl2, + MgCl2, without phenol red from 
).  200 µL sample volume (sterile nanoparticles
 in concentrations between 0.05 mg/m
 as a positive control and
 incubated for 6 h at 37 °C standard conditions
d and washed with HBSS once
L PBS) was diluted at a ratio of
. The liquid was removed followed by the addition 
 (DMSO) for 20 min. again at 37 °C and gentle shaking in 
-control. The relative viability was calculated as 
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5.2.1.3 MTS/PMS assay 
The main principle of the MTT and MTS/PMS assay [192] is basically the same. The 
MTS/PMS is often described as a ‘one-step’ MTT assay. Here, the tetrazolium dye 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoli-
um (MTS; reagent powder CellTiter 96® AQueous from Promega) is used in 
conjunction with the intermediate electron acceptor 1-methoxy phenazine 
methosulfate (PMS; < 90% (UV) from Sigma (P9625-500MG)) to produce a formazan 
product absorbance maximum at 490 nm intracellularly. Project partner conducted 
this assay concerning the following protocol: cells (A549) were seeded at 
9,000 cells/well (96-well plate) in 100 µL medium; cultured under standard conditions 
at 37 °C in a 5 % CO2 95 % humidified atmosphere for 24 h and incubated for 6 h. 
Sodium dodecyl sulfate (SDS; 10,000 µM) was used as positive control and buffer 
treated cells as negative control. Formulations and controls were prepared in 10 mM 
HEPES HBSS buffer instead of DMEM media. Growth medium was removed from 
cells and samples (predetermined concentrations) were added.  After 6h incubation, 
samples and controls were discarded and cells were washed two times with HBSS. 
Then MTS/PMS (final concentration: MTS 240µg/mL, PMS: 2.4 µg/mL) solution was 
added and incubated for 1.5 h at 37 °C with mechanical shaking and light protection. 
Absorbance was measured at 492 nm. The relative viability was calculated as 
described in section 5.2.1.3. 
 
5.2.1.4 ViaLight™ assay 
As a second method, to confirm privious cytotoxicity results from the MTT or 
MTS/PMS assay, the ViaLight™ Plus Cell Proliferation and Cytotoxicity BioAssay Kit 
from Lonza was used. Here, the amount of ATP (present in all viable and 
metabolically active cells) was measured via bioluminescence [193]. The enzyme 
luciferase catalyzes the formation of light from luciferin (both contained in ATP 
monitoring reagent) and ATP. Such a luciferase-based assay provides a sensitive 
and direct measurement of cell viability without distorting effects which might occur 
due to washing or medium removal steps. 
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The assay was performed on the following protocol: A549 cells  were seeded at 
9,000 cells/well (in 100 µL, 96-well plates) and cultured under standard conditions at 
37 °C in a 5 % CO2 95 % humidified atmosphere for 24 h. Sodium dodecyl sulfate 
(SDS; 10,000 µM) treated cells were used as positive control and buffer treated ones 
as negative control. Formulations and controls were prepared in 10 mM HEPES 
HBSS buffer. The growth medium was removed from cells and samples 
(predetermined concentrations) were placed on the cells and incubated for 6 h. After 
incubation, 50 µL cell lysis reagent were added and incubated for additional 10 min. 
Afterward, 100 µL cell lysate were transferred in a white-walled luminometer plate 
and 100 µL ATP monitoring reagent were added. After 2 min. of incubation at RT 
luminescence was measured.  
  
5.2.2 Immunogenicity  
Nowadays, the development of novel vectors for gene delivery focuses mainly on 
non-viral vectors because of safety issues. An often mentioned bottleneck of viral 
vectors is the arising immune response [194, 195] and an induction of inflammatory 
response which leads to degenerated tissue or cells [196]. Nevertheless, 
immunogenicity is a major concern of therapeutic biomacromolecular products. 
Hence non-viral vectors need to be tested for any possible immunogenic potential. 
Thus, these results may limit later necessary in vivo applications. Different assays 
are available which predict the immunogenicity of a delivery system. Within 
COMPACT two preliminary NF-кB dependent in vitro assays (dendritic cell 
maturation and toll-like receptor assay) were selected to interpret the activation data 
appropriately. All results were performed in cooperation with Marit deGroot, 
University of Utrecht, COMPACT partner in WP3 (P2b) according to Zeng et al. [197].  
Deviations in data analysis (e.g. applied particle concentrations) occurred due to two 
different measurement series (1st and 2nd generation formulations). For PLGA-Cs 
NPs additional NF-кB and Hsp70 activation assays were executed by Pharmacoidea. 
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5.2.2.1 Dendritic cell maturation assay 
Dendritic cells (DCs) belong to one group of antigen-presenting cells in our immune 
system [198].  Mature and activated DCs can stimulate naive T-lymphocytes (“T” for 
thymus = place of maturation) and thus initiate and modulate the immune response 
of the human body [199, 200]. As the distinction of subtypes among murine bone 
marrow-derived dendritic cells (mBMDC) is initially more apparent than among 
human DCs [201] mBMDCs will be used in both assays. Here, mBMDCs were 
cultured for one week, and the DDS plus controls [PBS buffer, LPS 
(lipopolysaccharide) and siRNA solutions] were added (partially in different 
concentrations: 1st generation 50 – 410 µg/mL and 2nd generation 5 – 150 µg/mL) 
and incubated overnight. DCs were separated from other bone marrow derived 
immune cells by their high expression of the membrane proteins CD11c (Integrin 
type I; transmembrane protein) and major histocompatibility complex class II (MHCII). 
The maturation of mBMDC was assessed by up-regulated CD40 and CD86 
expression (co-receptors in T-cell activation). The cells needed to be stained the next 
day with antibodies against all these proteins (CD11, MHCII, CD40 and CD86) and 
measured by flow cytometry. The percentage of the maturated DC is then calculated 
by the following formula: 
 (%] =  11L
fVghhf49f86f L77" ∗ 100
11LfVghhf L77"  
Living cells were gated using forward scatter (FSC) and side scatter (SSC). In this 
gate the dendritic cells were selected by CD11c (Allophycocyanin = APC, Exmax 
650 nm/Emmax 660 nm; red laser: 640 nm) and MHCII (Horizon-V450; Exmax 
404 nm/Emmax 448 nm; violet laser: 405 nm). The maturation of these dendritic cells 
was then assessed by gating the double positives for both CD40 
(R-phycoerythrin = PE, Exmax 496 nm/Emmax 578 nm; yellow-green laser: 561 nm) 
and CD86 (Fluorescein isothiocyanate = FITC; Exmax 494 nm/Emmax 520 nm, blue 
laser: 488 nm). 
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5.2.2.2 Toll-like receptor assay 
As part of the pattern recognition receptor (PRR) family, toll-like receptors (TLRs) 
[202] belong to the innate immune system and recognize specific pathogen-
associated molecular patterns (PAMPs) to differentiate between host and foreign 
structures.  
Table 5.1 Overview of human TLRs and their associated recognized antigens; blue: tested in 
TLR assay; extracellular = location on cell membrane, intracellular = location on endosomal or 
endolysosomal membrane.                   
Pam3CSK = triacylated polypeptide (cell-wall component), activator of the proinflammatory 
transcription factor NFкB; HKLM: heat-killed bacteria, Listeria monocytogenes; FSL1: synthetic 
diacylated lipoprotein (from Mycoplasma salivarium); Poly I:C = Polyinosinic:polycytidylic acid; 
LPS: lipopolysaccharide (from e. coli); FLA-ST (Pam2CGDPKHPKSF):  flagellin (from 
S. typhimurium); ODN = oligodeoxynucleotide; CL264: 9-benzyl-8 hydroxyadenine derivative (in para 
position it contains a glycine on the benzyl group); CpG = cytosine-phosphate-guanine. 
 recognized antigen agonist(s) Location 
 
TLR1 
 
Bacterial lipoproteins and 
peptidoglycans 
 
Pam3CSK 
 
Extracellular 
TLR2 Bacterial peptidoglycans 
(lipoproteins etc.) 
Pam3CSK, HKLM, FSL1 Extracellular 
TLR3 dsRNA Poly I:C Intracellular 
TLR4 Lipopolysaccharides (etc.) LPS Extracellular 
TLR5 Bacterial flagella FLA-ST Extracellular 
TLR6 Bacterial lipoprotein FSL1  Extracellular 
TLR7 ssRNA, bacterial and viral CL264, Imiquimod, 
Gardiquimod 
Intracellular 
TLR8 ssRNA, bacterial and 
viral, phagocytized 
bacterial RNA 
ssRNA40, ssPolyU Intracellular 
TLR9 CpG DNA ODN2006 Intracellular 
TLR10 Unknown - ? 
TLR11 Flagellin / Profilin - no functional protein 
found in humans 
 
 Chapter 5 - Cell viability and immunogenicity 
 
 
90 
They are a class of several proteins (TLR1 to TLR11 in humans) and are expressed 
on the membrane of leukocytes (DCs, macrophages, natural killer cells, T- and B-
cells), epithelial cells, endothelial cells and fibroblasts [203] or occur intracellularly. 
To measure human TLR activation TLR reporter cell lines, Human Embryonic Kidney 
293 cells (HEK-Blue™ hTLR2, 3, 4, 7 and 9; InvivoGen, France) were cultured and 
incubated with loaded and unloaded particles in concentrations between 72 – 
575 µg/mL (1st generation) and 11.25 – 370 µg/mL (2nd generation). 
 
5.2.2.3 NF-кB activation 
As part of the COMPACT project NF-кB activation assays were performed by 
Pharmacoidea (P18) under the direction of Tamás Letoha to investigate if PLGA-Cs 
NPs inhibit LPS- and TNF (tumor necrosis factor) -induced activation. L929 (mouse 
fibroblasts), SHSY-5Y (human neuroblastoma cells) and RAW264.7 (mouse 
leukemic monocyte-macrophages) cells were transformed respectively with 
pNF-κB-luc4 and pSV-2/neo plasmids [204]. Culturing each cell line for 24 h on 
luminoplates (3 x 104 cells/well) in DMEM + 10 % FBS cells were incubated with NP 
samples in concentrations between 0.0625 mg/mL and 2.0 mg/mL for 30 min. 6 h or 
16 h later the medium was removed. After washing and lysis of the cells (with 
20 µL/well Reporter Lysis Buffer from Promega) for 10 min. at RT. 20 µL/well from 
the substrate (from Promega) was added to measure luciferase activity (with a 
Luminoskan™ Ascent microplate luminometer from Thermo Scientific). Cells were 
treated 30 min. after the peptide treatment with TNFα (CAS No.: 94948-59-1, 
100 µg/mL); for TNF stimulation, with LPS (CAS No: 297-473-0; 100 ng/mL) for LPS 
stimulation and with PMA (Phorbol 12-myristate 13-acetate; CAS No.: 16561-29-8; 
100 nM) for PMA stimulation. 
Hsp70 activation assay: Transformed RAW264.7 macrophages with pNF-κB-luc4 
and pSV-2/neo plasmids were incubated for 30 min. at 40 °C followed by the same 
treatment as NF-кB activation assay (see above). 
All assays were performed in triplicates as mean ± SD. 
 
 5.3 Results and discussion
5.3.1 Cytotoxicity 
5.3.1.1 MTT 
Within this chapter coated PLGA
effects of the nanoparticulate system 
of PLGA-Prot, PLGA-Cs and PLGA
Figure 5.4 Evaluation of MTT assay
and 1.0 mg/mL on lung epithelial cells (A549 and Ca
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 determine toxic 
-3 cells. 
 
mg/mL 
 Initially, a benefit regarding cell viability due to a prior purification procedure of the 
particles was not apparent. In the comparison between both cell lines, Calu
showed a better resistance against high particle concentrations. As a res
calculation of LD50 values suffered from missing viability rates lower than 50
Table 5.2). Both cell lines tolerate relatively high particle concentrations. Starting with 
concentrations between 0.05 mg/mL and 0.25 mg/mL no toxic effects cou
observed. Applying concentrations higher than 0.5 mg/mL first effects of PLGA
NPs and PLGA-CatSt on A549 cells became visible. For PLGA
viability was limited to A549 and Calu
applying more than 0.5 mg/mL of particle suspension. At the latest after raising 
concentrations up to 1 mg/mL, all cells showed strong toxic effects. 
These results are not based on 
Considering that the particl
concentrations, a consequence for
buffer and thus less salts. Consequently
varying osmotic pressures may o
Table 5.2 Overview of LD50 values for
calculated from MTT-assay on A549 and Calu
n/a: poor fit due to low/no toxicity
In conclusion, PLGA-Cs NPs see
Calu-3 cells. LD50 values around 0.25 mg/m
to PLGA-Prot NPs with LD
with LD50 = 0.710 mg/mL – 
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-Cs NPs, however, 
-3 cells. Only 20% of viable cells survived, after 
 
an influence of the pure cationic material
e samples were diluted with buffer, to obtain necessary 
 higher particle contents is the presence of less 
, a different pH (NPs suspensions: pH ~ 5)
ccur and affect the cells. 
 purified (Vivaflow®50) and non-purified coated PLGA NPs 
-3 cells. All samples were filtrated (Minisart
 
m to have the highest toxic effect on A549 and 
L confirm a stronger limitation in contrast 
50 = 0.438 mg/mL – 0.472 mg/mL and PLGA CatSt NPs 
0.885 mg/mL. 
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 only. 
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®
, 0.22 µm). 
 
 5.3.1.2 MTS/PMS assay
Divergent from the experimental setup in section
applied on A549 cells additionally
mechanism, results of prior studies
Figure 5.5 independent of the particle coating, the 
significant impact on cell viability
Figure 5.5 Evaluation of MTS/PMS assay
0.05 mg/mL and 1.0 mg/mL) on A549 cells. Non
loaded NPs samples were applied.
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 follow the same 
 
 Additionally, as already seen in MTT assays, purified NPs showed roughly the same 
results as non-purified samples. 
seem to be the most harmful type of coated nanoparticles
After incubation with PLGA
to 20 % at a concentration of 1
100 %) over the entire dilution series of PLGA
damaging effect at particle concentrations <
broader standard deviation at the highest 
Concerning later planned s
with macrophages on top, preliminary studies
investigate differences between stimulated and non
Figure 5.6). 
Figure 5.6 Evaluation of MTS/PMS assay: PLGA
0.1 mg/mL and 1.0 mg/mL) A: stimulated (p71) and 
Although using the MTS/PMS assay with a reduced amount of washing steps, cells 
were influenced by the analyt
level of ~ 60 % for stimulated and 
up to 0.5 mg/mL. The Viability of both 
applying a particle concentrat
macrophage-like cells were less robust than epithelia
THP-1 cells were even more
considering the activation process which means ad
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 and not PLGA
-Prot-NPs, cell viability dropped from 80
 mg/mL whereas cells kept viable (
-Cs NPs. For PLGA
 0.5 mg/mL could be observed; merely a 
of all tested concentrations
tudies on co-culture models consisting of epithelia
 with PLGA-Cs NPs were 
-stimulated THP
-Chitosan NPs (in concentrations between
B: non-stimulated (p72) THP-1 cells
ical procedure and showed a generally reduced viability 
 
~ 40 % for non-stimulated cells for concentrations 
types of THP-1 cells became 
ion of 1 mg/mL. Consequently, THP
l cells. Moreover, 
 affected by particles. This result is comprehensible 
ditional stress for treated cells. 
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LGA-Prot NPs 
-Cs NPs. 
 % for 0.5 mg/mL 
approximately 
-CatSt NPs no 
. 
l cells 
conducted to 
-1 cells (see 
 
 
. 
reduced by 50 % 
-1 cells as 
activated 
 
 5.3.1.3 ViaLight™ assay
As ViaLight™ assays are known to be more sensitive than colorimetric viability 
assays higher standard deviations (especially with increasing particle concentrations) 
need to be mentioned. For PLGA
a slight reduction of viability by 
1.0 mg/mL. 
Figure 5.7 Evaluation of the ViaL
0.1 mg/mL and 1.0 mg/mL) on A549 cells. Non
loaded NP samples were applied
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 At first sight, a gradually increased
rising PLGA-Cs NP concentrations
explained by toxic effects
metabolism. Hence, higher values were a result of cellular stress against 
factors. The same tendency could be observed for PLGA
less pronounced.  
 
5.3.2 Immunogenicity
5.3.2.1 DC maturation assay
Within the COMPACT consortium PLGA
well as 2nd generation formulations (PLGA
independently from another which caused a different evaluation
results. In the series of 2nd generation test 
as negative control were applied.
or amounts of cells on y
comparison of all results was not possible, but a relative description of the tendency 
from changing particle concentrations was sufficient. 
Figure 5.8 Evaluation of dendritic cell maturation assay; mean fluorescent intensity (MFI) is plotted 
against applied PLGA-Cs samples;
This assay (see Figure 5.7) 
CD86 (protein on antigen-presenting cells
t-cell activation) and CD40 (co
bone marrow derived dendritic cells in a dose
The assay testing 2nd generation formulations 
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 cell viability of A549 cells after in
 was not expected. However, these results 
 which occur when cells react with an increased 
-CatSt NPs even though 
 
 
-Cs NPs as 1st generation formulation
-Prot and PLGA-CatSt NPs) were tested 
differentparticle concentrations
 Activation results measured as fluorescent intensity 
-axis; see Figure 5.8 and 5.9, respectively
 
 
 PBS as negative control and LPS as positive control.
showed a minor up-regulation of co-stimulatory factors 
, which provides co-stimulatory signals for 
-stimulatory protein on antigen-presenting cells) on 
-dependent manner for
showed a minimal DC activation of 
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PLGA-Prot NPs and a minor activation of PLGA-CatSt NPs at highest 
concentrations, respectively. Thus, results of PLGA-CatSt NPs directly correlated 
with cell growth and cell viability. 
 
Figure 5.9 Evaluation of dendritic cell maturation assay; amount of cells is plotted against applied 
2nd generation formulations; HEPES and HEPES+PVA as negative control and LPS as positive 
control. PLGA-Prot NPs (purple, left), PLGA-Prot NPs + siRNA (purple, right), PLGA-CatSt NPs (blue, 
left), PLGA-CatSt (blue, right) and siRNA (green); SEAP = Secreted Alkaline Phosphatase. 
 
5.3.2.2 TLR assay 
Within this chapter, human TLR activation of different subtypes was tested. PLGA-Cs 
NPs (see Figure 5.10) showed no TLR2, 4 and 9 activation. A possible effect of TLR3 
was not assessable as controls showed a lower activation than by the positive ligand 
(false negative results were possible). The analysis of the first generation formulation 
did not include TLR7 (endosomal ssRNA), which was available for the following 
developed formulations. Hence, a later evaluation of the activation of TLR7 by PLGA-
Cs NPs needs to be performed to complete this data set. 
Having a look at the results of the TLR2 (see Figure 5.11) and TLR4 (data not 
shown) activation assay, no significant results from PLGA-CatSt and PLGA-Prot NPs 
were observed.  
 
 Figure 5.10 Evaluation of TLR 
samples; water as negative control 
Figure 5.11 Evaluation of TLR2 activation assay; 
formulations in µg/mL; HEPES and HEP
control. PLGA-Prot NPs (purple), PLGA
Alkaline Phosphatase 
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Figure 5.12 Evaluation of TLR3 activation assay; activity is plotted against applied 2nd generation 
formulations in µg/mL; HEPES and HEPES+PVA as negative control and PolyI:C as positive control. 
PLGA-Prot NPs (purple), PLGA-CatSt NPs (blue) and siRNA (green). SEAP = Secreted Alkaline 
Phosphatase. n.a. = not available because false negatives failed 
A similar observation was made for TLR3 (see Figure 5.12), TLR7 and TLR9 (data 
not shown): no activation of TLR 3 and 7 by PLGA-Prot NPs was found, whereas no 
assessable results for TLR9 (both particles) and TLR3, 7 and 9 activation (PLGA-
CatSt NPs) were obtained (see above). Table 5.3 shows an overview about obtained 
immunogenicity results. In conclusion, PLGA-Prot and PLGA-CatSt marginally 
activated DCs at higher concentrations (> 150 mg/mL). This activation was not 
caused by TLR2, 3, 4, 7 or 9 activation and was independent of siRNA loading. As 
PLGA-CatSt particles induced excessive growth of cells, an activating effect may be 
caused by other factors as immunogenicity. 
Table 5.3 Overview of DC maturation and human TLR activation results. x = result is not available; 
o = negative result without verification (system may bind to TLR3, TLR7 and TLR9 control); 
plus (+) = human TLR activation; minus (-) = no human TLR activation. 
  mDC hTLR2 hTLR3 hTLR4 hTLR7 hTLR9 
siRNA - - - - - - 
PLGA-Prot - - - - - O 
PLGA-Prot-siRNA - - - - - O 
PLGA-Cs (+) - o - X - 
PLGA-Cs-siRNA (+) - o - X - 
PLGA-CatSt + - o - O O 
PLGA-CatSt-siRNA + - o - O O 
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5.3.2.3 NF-кB and Hsp70 activation assay 
PLGA-Cs NPs and free Chitosan showed a modest NFκB activation in L929 
fibroblasts, SHSY-SY neuroblastoma cells, and RAW264.7 macrophages. The 
cellular response towards proinflammatory stimuli (TNFα, LPS, PMA) was reduced 
when cells were pretreated with PLGA-Cs NPs. However, this effect was based on a 
partly dose-dependent manner. Here, the highest reduction was observed at 
RAW264.7 cells followed by L929 and SHSY-SY cells. The lower impact on SHSY-
SY cells might be caused due to lower uptake rates. Additionally, Hsp70 was only 
activated at the highest particle concentration of 2 mg/mL. As some inconclusive 
results were measured (rather low LPS effect on RAW264.7 cells and a decreased 
NFκB signal without prior proinflammatory stimuli) these results need to be repeated 
to exclude possible implementation errors. 
 
5.4 Conclusion 
As MTT assays are prone to interference due to culture condition changes, the 
COMPACT consortium decided to use MTS/PMS due to its increased sensitivity 
[205, 206] and fewer required steps (to avoid additional cell stress). However, MTT 
was very robust and metabolized by most cell lines [207]. The ViaLight™ as an ATP 
detection assay is by far the most sensitive one [208], but results suffered from high 
standard deviations and rising viabilities for PLGA-Cs and PLGA-CatSt NPs. 
Considering all viability assays, all three types of delivery systems showed no or 
merely less cytotoxic effects at applied concentrations. 
All three types of coated PLGA NPs slightly activated BMDCs (see section 5.3.2.1) at 
concentrations above 150 µg/mL. This activation was not caused by TLR2 and TLR4 
activation and was independent of siRNA loading. The coated PLGA NPs also did 
not activate the TLR3, 7 and 9 reporter cell lines. But as they reduced agonist-
mediated activation, this observed lack of activation of TLR3, 7 and 9 (detection of 
double-stranded RNA, single-stranded RNA, and CpG DNA) may be explained by 
the desired ability of the DDS to bind and deliver nucleic acids in general. As PLGA-
CatSt caused excessive cell growth, CatStarch seemed to be a ‘self-adjuvant’ 
polymer. 
 Chapter 5 - Cell viability and immunogenicity 
 
 
101 
PLGA-Cs NPs showed merely marginal NFкB and Hsp70 activation. Clearer results 
need to be acquired from further investigations. Nonetheless, in-vivo biodistribution 
studies of loaded DDSs using ALEXA750-labeled siRNA in mice have been planned 
and will be conducted soon.   
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6.1 Introduction  
Within this chapter, the ability of coated cationic polymer-based DDS as a vector to 
transfect cell culture cells was investigated. A Luciferase assay is a commonly used 
technique to show the efficacy of a potential transfecting agent or a gene delivery 
system. Here, pGL3 plasmid DNA (pDNA; plasmid which encodes the production of 
Luciferase protein) will be internalized into eukaryotic culture cells. After applying a 
matching siRNA, the measurement of the luminescence should show a knock-down 
of the luminescence signal. As transiently transfected cells are known to lose their 
foreign genetic information from the plasmid (usually within 24 - 96 hours) due to 
proliferation processes (cell division and other factors) a stably transfected cell line is 
necessary for valid knock-down results. Such a cell line with a remaining pDNA 
construct can be created by a transient transfection followed by serendipitous 
integration of the gene into its genome for its replication. A co-expression of a 
selection marker (e.g. antibiotic resistance) ensures the cultivation of desired clones. 
However, hard-to-transfect cell lines, especially primary cells, require viral methods 
(e.g. transduction). These methods suffer from time-consuming production of 
necessary vectors and safety concerns [209]. 
As part of the COMPACT consortium stably transfected BHK (baby hamster kidney 
fibroblasts; EGFP-transfected) cells and HeLa (immortal cervical cancer; eGFP and 
Luciferase-transfected) cells were provided by project partners. Here, plasmid DNA 
(pGL3 = pDNA: plasmid which encodes production of Luciferase protein and/or eGFP 
(enhanced green fluorescent protein) has been integrated into cell culture cells. 
Unfortunately, the signal intensity when the cells were cultivated in-house was not 
evolved sufficiently. Therefore, and due to the lack of time the development of a new 
experimental setup to show a knock-down after transfection without the availability of 
a stably transfected cell line was necessary. Additionally, a proper transfer of results 
from BHK or HeLa cells to human lung cell models (cell line or primary cells) is 
vague.  
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6.2 Materials and methods 
In the following section different transfection agents were applied to identify the most 
suitable positive control for later studies on lung specific cells.  Lipofectamine® 
RNAiMAX reagent (from Invitrogen by Life Technologies, USA), siPORT™ NeoFX™, 
a lipid-based transfection agent (from Ambion by Life Technologies, USA), 
jetPRIME™ and INTERFERin™ (from Polyplus transfection, France), and 
HighPerFect, a blend of cationic and neutral lipids for transient transfection, (from 
Qiagen) were considered. Furthermore, all RNase sensitive samples were bottled 
into DNA LoBind Eppendorf Tubes® 1.5 and 5 mL from Eppendorf AG, Germany. For 
normalization a quantification of the protein amount was conducted via Microplate 
BCA™ Protein Assay Kit – Reducing Agent Compatible from Thermo Scientific and 
pGL3 plasmid was extracted and purified  using Plasmid Mega-Kit from QIAGEN 
from an E.coli DHA-alpha culture strain. Luciferase 1000 assay system was 
purchased from Promega. Transwell® (12-well Transwell® plates 3460 with polyester 
membrane Transwell®-inserts, pore size: 0.4 µm, growth surface area: 1.12 cm2 were 
used to measure TEER values in Ω* cm2 (e.g. hAELVi B/15 p 36 20.4.15; 
blanc = 110; barrier > 300). Luciferase plasmid pGL3 was extracted and purified in-
house (see section 6.2.2) and siRNAs (negative control and pGL3 matching 
sequence) were provided from COMPACT partner GSK and Luciferase GL3 duplex 
(target sequence: CUUACGCUGAGUACUUGA) was purchased from Dharmacon. 
Additional materials, chemicals and media are listed in the related sections. All 
experiments were conducted in triplicates 
 
6.2.1 Cultivation of A549 and hAELVi cells  
 
Epithelial cell line 
Adenocarcinomic human alveolar epithelial cells (A549; ATCC® No. CCL-185™) 
[187] from ‘American Type Culture Collection’ (ATCC) were cultivated as previously 
described in section 5.2.1.1. 
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Immortalized lung epithelial cells  
hAELVi.B (human alveolar epithelial lentivirus immortalized, clone B) [210] cells were 
cultivated in small airway epithelial cell basal media (Clonetics® SABM™ medium 
from lonza, Walkersville, USA); with 1 % Penicillin-Streptomycin (PenStrep: Penicillin 
10,000 U/mL, Streptomycin 10,000 µg/mL; Gibco by Life Technologies, USA), 
1% fetal bovine serum (FBS; from Lifetechnologies, Germany), supplied with growth 
factors (Clonetics® SABM™ SingleQuots® from lonza, Walkersville, US) to convert 
SABM™ Basal Medium to SAGM™ Growth Medium (small airway growth medium). 
500 mL contain BPE (bovine pituitary extract), 2.0 mL; Hydrocortisone, 0.5 mL; 
rhEGF (recombinant human epidermal growth factor), 0.5 mL; Epinephrine, 0.5 mL; 
Transferrin, 0.5 mL; Insulin, 0.5 mL; Retinoic Acid, 0.5 mL; Triiodothyronine, 0.5 mL; 
GA (gentamicin 30mg/mL, amphotericin 15 µg/mL), 0.5 mL; BSA-FAF (bovine serum 
albumin, fatty acid free), 5.0 mL at 37 °C in 95 % humidified air (5 % CO2). To enable 
cell attachment Cellstar® T75 standard cell culture flasks, Cellstar® 24-well cell 
culture plates (both from greiner bio-one) and Transwell® polyester membranes 
(Corning 3460 with a pore size of 0.4 µm) were coated with 1 % (v/v) fibronectin 
(Corning, USA) and 1 % (v/v) collagen (from bovine skin; Sigma, Germany).  
In contrast to A549 cells which are incapable of forming a functional barrier hAELVi 
cells express tight junctions. These barrier properties roughly correspond to the 
situation in-vivo. Measurements of the transepithelial electrical resistance (TEER) 
were conducted by a heating plate at 37 °C to avoid temperature-dependant 
influences  using a chopstick electrode coupled with an epithelial Volt/Ohm meter 
(EVOM, from World Precision Instruments, USA) and describe the integrity of a cell 
layer [54]. For this purpose, cells were seeded at a density of 100,000 cells/cm2 on 
Transwell® membranes and cultivated under liquid covered conditions (LCC: 500 µL 
apical compartment and 1.5 mL basolateral compartment) and measured on day 4, 
6, 8, 11 and 12. TEER values were calculated by consideration of resistance values 
(110 Ω) of cell-free inserts containing only medium with a cultivation area of 
1.12 cm2. 
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6.2.2 Extraction of pGL3 plasmid from E.coli 
Bacterial cells from the culture strain E.coli DHA-alpha (genotype: F– Φ80lacZΔM15 
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1) containing pGL3 plasmid were used as starting material to extract the 
pGL3 vector. To purify the amount of plasmid DNA the Plasmid Mega-Kit from 
QIAGEN was used as recommended in the associated protocol. The DNA 
concentration was determined by UV spectrophotometry at 260 nm (Eppendorf 
BioPhotometer) and diluted with TE-buffer (10 mM Tris, 1 mM EDTA; pH 8.0) to a 
final concentration of 1 µg/mL, aliquoted and stored at – 20 °C (- 80 °C for long term 
storage). 
 
6.2.3 Simultaneous co-transfection 
As the application of a stably pGL3-transfected cell line was not applicable, a 
simultaneous co-transfection was used to analyze transfection efficiencies of the 
investigated DDSs. Performing this experiment attention should be paid to the fact 
that pGL3 plasmid (200 ng/well) and siRNA (600 ng/well) solutions (diluted with 
medium to obtain a final sample volume of 100 µL/well) were separately incubated 
with 1 µL/well of transfection agent (Lipofectamine® RNAiMAX from Invitrogen by Life 
Technologies, USA) to ensure a proper polyplex formation. Afterward a mixture of 
plasmid- and siRNA-complexes was feasible. To exclude a possible source of error 
by deficient siRNA a Luciferase GL3 duplex (from Dharmacon, Inc., USA) was tested 
next to the provided COMPACT pGL3 siRNA (from GSK).   
Prior studies (see section 6.2.4) confirmed sufficient transfection experiments when 
FBS is present in cell culture medium. Thus, A549 cells were seeded in RPMI 
medium containing 10 % FBS at a density of 30,000 cells/well and hAELVi cells in 
SAGM containing 1 % FBS at a density of 50,000 cells/well (both in 24-well cell 
culture plates). After reaching a confluence of 80 – 90 % cell culture medium was 
replaced and 100 µL/well sample solution were applied followed by 24 h of incubation 
at standard conditions. Here, 100 µL sample solution contained 200 ng pGL3 plasmid 
+ 1 µL transfecting agent and 600 ng siRNA + 1 µL transfecting agent as a positive 
control or bound on coated PLGA NPs in a ratio of 1:50 (siRNA:NP), see section 
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2.3.3. For negative controls, the volume of transfecting agents was replaced by 
medium or only pGL3 plasmid. Additionally, a transfecting agent was applied. After 
incubation sample solutions were discarded, cells were washed with PBS buffer and 
100 µL/well lysis buffer were added (incubation for 10 min. at RT). BCA-RAC assay 
and Luciferase assay were conducted as described in section 6.2.5 (BCA-RAC 
assay) and 6.2.6 (Luciferase assay). 
  
6.2.4 Screening of transfection reagents  
Depending on the experimental setup of transfection trials and the chosen cell line 
different commercially available transfection reagents may be suitable as a positive 
control. In this connection, a positive control has to show a possibly high impact on 
applied cells which is commonly evaluated by the respective manufacturer for 
standard cell lines. As in this chapter co-transfection experiments on A549 and 
hAELVi.B cells were performed, a prior screening of competing transfecting agents 
on both introduced cell lines was necessary.  
A549 cells were seeded in RPMI medium with 10 % FBS and without FBS at a 
density of 30,000 cells/well (24-well cell culture plate) and hAELVi cells in SAGM with 
1 % FBS in a density of 50,000 cells/well (24-well cell culture plate). After reaching a 
confluency of 80 - 90 % (incubation under standard culture conditions for 
approximately 3 days) transfection experiments could be initiated: medium was 
replaced and plasmid (200 ng/well) and siRNA (600 ng/well) were mixed separately 
with respectively 1 µL/well transfection reagent. After incubation for 15 min. at RT 
(formation of complexes) both mixtures were combined and medium or reagent 
buffer was added to obtain a final volume of 100 µL/well. For controls transfection 
reagent was substituted by medium. 100 µL/well transfecting mixture were added 
and cells were incubated for 24 h under standard conditions. Subsequently, cells 
were washed with PBS buffer, 100 µL/well lysis buffer were added and cells were 
incubated for 10 min. at RT. BCA-RAC assay and Luciferase assay were conducted 
as described in section 6.2.5 (BCA-RAC assay) and 6.2.6 (Luciferase assay). 
 
 6.2.5 BCA vs. BCA-
To analyze a Luciferase assay 
signal = relative light units (RLU) 
commonly used method for normalization is the determination of the entire amount of 
protein via bicinchoninic acid assay
Scientific). To create a Luciferase as
Lysis reagent (CCLR; from 
water.  
Figure 6.1 Comparison of the effect of reducing agents
protein assays; A/B: samples contain 5 mM DTT and 
µg/mL from tube 1 to 8: 0, 125, 250, 500, 750,
lysis buffer (among others 2 mM DTT
concentrations in µg/mL from left to right: 0, 100, 400, 600, 800, 1000. 
www.thermoscientific.com/order/catalog/product/23252
The composition of this (1x) buffer according to the 
System – Technical Bulletin No. 281 is
2 mM DTT, 2 mM 1,2-diaminocyclohexane
1 % Triton® X-100. The high concentration of dithiothreitol (DTT) and detergent 
(Triton® X-100), however, 
protein quantification assays (see Figure 6.1). 
(Pierce™ Microplate BCA Protein Assay Kit 
Thermo Scientific) was used. This specific 
DTT up to 5 mM and Triton
Here, after 24 h of incubation sample solutions were discarded and cells were 
washed with PBS buffer. After the addition of 100
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10 min. of incubation, 9 µL cell lysate were transferred in a 96-well plate and 
incubated again with 4 µL compatibility reagent solution for 15 min. at 37 °C. 
Afterwards 260 µL BCA-reagent were added and the 96-well plate was covered and 
incubated for 30 min. at 37 °C. Using the standard control as blank the absorbance 
rates of cool (RT) sample controls and standards (bsa: 0 – 2,000 µg/mL) were 
measured at 562 nm with a Tecan® Infinite 200 PRO multimode microplate reader 
(using i-control™ software; Tecan Deutschland GmbH, Germany). 
 
6.2.6 Luciferase assay 
Here, the Luciferase 1000 assay system from promega was used. After 24 h sample 
incubation cells (in 24-well cell culture plate) were washed with 500 µL PBS buffer. 
As much waste as possible was removed followed by the addition of 100 µL lysis 
buffer (incubation 15 min. at RT). Cell lysate (20 µL/well) was transferred into an 
OptiPlate™-96 white (from PerkinElmeer, USA). 100 µL of Luciferase reagent 
(protected from light exposure) were added via auto-injector, and the emitted light (as 
relative light units = RLU) was immediately measured via Tecan® Infinite 200 PRO 
multimode microplate reader (using i-control™ software; Tecan Deutschland GmbH, 
Germany). This step was repeated for the remaining wells. 
 
6.3 Results and discussion 
6.3.1 Reagent screening 
Depending on the deployed transfection agent and the selected cell type results of 
co-transfection experiments with Luciferase (pGL3) plasmid and siRNA showed 
enormous differences. Within this study, agents needed to be capable of transfecting 
plasmid DNA and siRNA at the same time. Differences between (-) non-matching 
siRNA and (+) pGL3-matching siRNA were evaluated and indicated the knock-down 
ability of the reagent, which was the determining value identifying a positive control.  
 Figure 6.2 Screening of different transfection reagents on A549 cells cultivated without F
with 10% FBS (B). Minus (-) indicates a transfection with a negative control siRNA and plus (+) 
indicates a transfection with a L
partner gsk). 
Within this study (see Figure 6.2) HighPerFect showed only a weak light em
the transfected Luciferase plasmid and almost no knock
A549 cells. Similar results could be obtained for siPORT
First knock-down tendencies showed I
from the (-) siRNA control and a slightly reduced signal 
siRNA. On A549 cells (Figure 6.2 A: 
RNAiMAX were sufficient in transfecting pGL3 L
whereas only Lipofectamine RNAiMAX could
exposure. In FBS containing RPMI medium
significant reduction of the L
failed in inducing high amounts of l
efficiency of a transfection agent is dependent on the selec
between A549 and hAELVi cells were expected. Here, only Lipofectamine RNAiMAX 
was able to show an adequate knock
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without FBS) jetPRIME and Lipofectamine 
uciferase plasmid into the cells
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 (Figure 6.2 B) both reagents achieved 
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´Luciferase plasmid compared to jetPRIME. As the 
ted cell line, differences 
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 Figure 6.3 Screening of different transfection reagents on hAELVi cells c
Minus (-) indicates a transfection with a negative control siRNA and plus (+) indicates a transfection 
with a Luciferase (pGL3) knock-down siRNA.
All other reagents showed 
apparently transfected the L
visible). In conclusion, Lipofectamine RNAiMAX had the best accordance 
transfection results on A549 and hAELVi cells. 
represents the positive control fo
 
6.3.2 Transfection experiments
The transfection efficiency of a developed carrier is one essential parameter when 
comparing several drug delivery systems. Figure 6.4 
coated PLGA-based particulate systems loaded 
project-internal Luciferase 
siRNA (Dha +; Luciferase duplex from Dharmacon).
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 Figure 6.4 Evaluation of simultaneous co
indicates a transfection with a COMPACT intern
pGL3 duplex from Dharmacon. Minus (
PLGA-Prot (blue), PLGA-Cs (yellow) and PLGA
as a positive control. 
Following previous results (see section 6.3.1) Lipofectamine RNAiMAX was applied 
as a positive control and complexed with pGL3 plasmid DNA and siRNA (
Dha +). As the addition of Lipofectamine 
the same RLU level, results of NPs with non
obtain a coherent evaluation.
commercial Dharmacon duplex and COMPACT siRNA occurred. 
acids were intact and efficient
better knock-down ability than the positive control. Nevertheless, differences could be 
observed depending on the particle coating
buffering capacity (see section 3.2.3.2) and 
charge (see, section 3.3.2.1)
factors (e.g. loading efficiency). 
characteristics of the DDS and 
down of PLGA-Cs NPs and an increased down
this study. As a result, simultaneous 
siRNA worked even though the efficiency could not be predicted by prior determined 
characteristics. 
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 Some but non-significant differences between the 
Thus,
. All investigated particulate systems seemed to 
. Although Protamine showed a minimal 
PLGA-Prot NPs the slightest surface 
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-, + and 
 almost 
 both nucleic 
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 of various 
reduced knock-
CatSt NPs within 
and 
 6.3.3 Transfection of hAELV
hAELVi cells show enlarged generation times 
more cells (50,000 cells/well
confluence of ~ 80 %. Apart from this
was applied to investigate transfection efficiencies on hAELVi cells (see Figure 6.5).
Here, all obtained values (RLU/µg protein) showed a lower 
improved barrier properties of hAELVi cells compared to A549 cells. Regarding 
differences within applied samples the 
PLGA-Cs NPs showed similar
could induce an enhanced knock
prior assumptions more than one parameter seemed to be responsible for
improved transfection as observed deviations on A549 and hAELVi 
specific.  
Figure 6.5 Evaluation of simultaneous co
indicates a transfection with a COMPACT intern
pGL3 duplex from Dharmacon. Minu
PLGA-Prot (blue), PLGA-Cs (yellow) and PLGA
as a positive control. 
Based on previous results, possible transfection 
functional barrier properties were evaluated. For this purpose cells needed to be 
cultivated on Transwell® membranes to enable TEER measurements (see Figure 
6.6). After cultivating cells for 11 days increased TEER values indicated an intact 
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which confirmed 
-Prot NPs and 
-CatSt NPs 
, confirming 
 an 
were solely cell 
 
 cells. Plus (+) 
Luciferase 
 cells with 
 cellular monolayer and represented the starting point for additional transfection 
studies. Unfortunately, no significant 
measured. In conclusion, 
system with barrier performing cells. 
Figure 6.6 Barrier properties of 
12 days. 
 
6.4 Conclusion 
Within this chapter, the ability of a nanoparticulate system to transfect lung
cells was investigated. After identifying Lipofectamine RNAiMAX as a suitable 
positive control and BCA
functioning simultaneous transfection with pGL3 plasmid and siRNA
partly on hAELVi cells (no transfection
cells) was shown. However, 
These cell-specific differences can be
[211, 212] of A549, whereas h
transfection experiments required a transfection agent to transfect a 
plasmid, all samples contain this reagent (with an unknown composition). Hence, 
possible interactions between cells, applied materials and transfection agent can 
never be excluded.  
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Consequently, initial results need to be verified by other transfection studies. One 
possibility would be measuring the knock-down of an endogenous gene via GAPDH 
siRNA, followed by qPCR analysis. Another approach could be the investigation of 
stable Luciferase/eGFP transfected A549 and hAELVi cells, as transfection studies 
on BHK1 and HeLa cells showed merely limited effects. Furthermore, the 
combination of Luciferase and eGFP shows the advantage of holding two 
comparable knock-down parameters within one cell line. Following this, a transfection 
of hAELVi cells under air-liquid interface (ALI) or LLC as well as on co-culture models 
(hAELVi plus THP-1 cells) needs to be performed (in co-operation with COMPACT 
partners in WP 6).  
In-vivo transfection studies with transgenic mice needed to be postponed, as murine 
TNFα antisense was not available and the animal model needed to be established 
first, at that time. 
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The author of this thesis made the following contribution to this chapter: 
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FCS analyses were performed by Edward Sayers at Cardiff University. He analyzed 
data from the mentioned studies and interpreted the experimental data. 
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7.1 Introduction 
Different transport mechanisms on how substances or particles can reach their target 
are known. A distinction is made between paracellular transport between cells and 
through their tight junctions, transcellular transport through cells (including 
receptor-mediated transcytosis) and intracellular transport into cells. The paracellular 
transport is restricted to solutes with a maximum diameter of 6 nm [213] and the 
transcellular transport usually to macromolecules like transferrin, insulin,  IgA or 
lipophilic NPs [214]. The primary transport mechanism for our polymeric carrier 
systems seems to be the latter one, the intracellular transport, which is also 
described as endocytosis.  
When a particle hits the cell surface, it cannot simply pass through the cell 
membrane. But an energy-using process can be initiated. Depending on the 
properties or characteristics of a particulate system (size, shape, hydrophobicity of 
applied materials and ligand attachments) [215] the cellular internalization can be 
classified into different submechanisms: phagocytosis, macropinocytosis, 
clathrin-mediated and caveolae-mediated endocytosis. The last three pathways 
belong to the umbrella term pinocytosis. Pinocytosis in general, also known as “cell 
drinking”, is describing the uptake of extracellular fluids and the substances it 
contained. 
After engulfing the particulate system, endosomal vesicles (or primary vesicles) will 
be formed, and the endocytic pathway starts by routing them to early endosomes. 
This organelle is mainly located in the cell periphery and can be described as a 
cargo-sorting station [216]. The lumen of an early endosome is slightly acidic 
(~ pH 6.0 - 6.8) [217, 218] where ligands dissociate from their receptors. The material 
from the early endosome will be delivered to a late endosome with an acidic pH of 
5.5 and finally to the lysosome, the last compartment of the endocytic pathway where 
ligands are degraded by the lower pH of 4.5 – 5.0 [219]. In the following section, the 
terms endosome and lysosome (here, a differentiation via CLSM is not possible) will 
be used interchangeably. 
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7.2 Materials and methods 
7.2.1 Cell culture 
Different lung-specific cells of human origin and other non-pulmonary cells were 
available and seeded at 20,000 cells/well (19,600 cells/cm2) in 8-well cell culture 
slides (No. 30118 from SPL life technologies, Chosun) for uptake and localization 
studies. 
 
7.2.1.1 Lung cells 
Human monocyte-derived cells (THP-1), adenocarcinomic human alveolar epithelial 
cells (A549) and adenocarcinoma-derived human bronchial epithelial cells (Calu-3) 
were cultivated as described previously in section 5.2.1.1. For FCS analysis 
A549 cells were seeded at 200,000 cells (270,000 for initial uptake studies) per 
imaging dish (from MatTek Corporation, USA) and incubated for 24 h. Detailed 
information about cultivating hAELVi cells can be found in section 6.2.1. 
 
7.2.1.2 Non-pulmonary cells 
Prior experiments indicated cell specific transfection efficiencies particularly due to 
their specific uptake behavior. Although studies within this work were focused on 
lung-specific cells, a varying particle uptake depending on the applied cell line was 
investigated. Briefly, Normal Human Dermal Fibroblasts (NHDF-p) as proliferating 
cells, next to immortalized Human Skin keratinocytes (both cultivated in Dulbecco’s 
Modified Eagle Medium, DMEM; plus 10 % FBS) and HeLa cells, the oldest 
immortalized human cell line taken from cervical cancer from Henrietta Lacks 
(cultivated in Eagle’s Minimum Essential Medium, EMEM from Lonza; plus 10 % FBS 
and 1 % PenStrep), were evaluated. 
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7.2.2 Uptake and localization 
Confocal laser scanning microscopy (CLSM) was used to visualize different cell 
compartments and engulfed NPs. For fixation, cells were washed with PBS first, 
followed by the addition of 200 µL MeOH (ice chilled) for 15 min. at 4 °C. Hereafter, 
MeOH was removed and cells were washed again with PBS. To stain the cellular 
membrane 200 µL Rhodamine-labeled Ricinus Communis Agglutinin I (RCA I from 
Vector Laboratories; diluted 1:1,000 in PBS) were incubated for 10 min. at RT. After 
washing with PBS, cells were counterstained with 200 µL 4',6-diamidino-2-
phenylindole (DAPI; CAS No.: 28718-90-3; nuclei stock: 1 mg/mL from Life 
Technologies™, Germany; diluted 1: 50,000 in PBS) for 20 min. at RT. Finally, cells 
were washed again with PBS. Fixed and stained cells were analyzed by CLSM 
(Zeiss LSM710, Zeiss, Germany) equipped with a 63 x water immersion object lens. 
Obtained images were edited by Zen2012 software (Carl Zeiss Microscopy GmbH, 
Germany). Settings were optimized to each sample except for correlative 
microscopy. Here, settings were kept the same for all samples to enable 
comparability. 
To confirm a particulate uptake into cellular endosomes a lysosomal staining (of 
selective accumulated weakly basic amines into organelles with a low pH [220]) was 
applied. Therefore, living cells were incubated with FA-labeled NPs (30 µg/mL) for 24 
h at 37 °C, followed by 200 µL LysoTracker® Red (DND-99; Abs: 577 nm; 
Em: 590 nm; 1 µL in 5 mL PBS) for 2 h at 37 °C. 
For initial uptake studies on viable THP-1 cells loaded (1:5 ratio of ALEXA-labeled 
siRNA and non-labeled siRNA in a total ratio of 1:100 siRNA:particles) FA-PLGA-Cs 
NPs (0.1 µg/mL) were incubated for 24 h in FBS-free medium. 
 
7.2.4 Fluorescent correlation spectroscopy 
In cooperation with Edward Sayers, Cardiff University, a COMPACT partner in WP3 
(P5) the particulate systems were tested regarding particulate binding and uptake 
into cells. Here, A549 cells were exemplarily used for a pulmonary alveolar epithelial 
cell model. After determining the suitability of the flu-labeled particles (coated 
FA-PLGA NPs) for microscopy and fluorometry FA-labeled PLGA NPs were loaded 
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by adding an aqueous solution of siRNA (1:5 ratio of ALEXA-labeled siRNA and 
non-labeled siRNA) in a ratio of 1:100 (siRNA:particles) and subsequently diluted 
with serum containing medium (SCM) down to 100 µg/mL. For initial uptake studies 
samples were immediately added to the cells and incubated for 1 h at 37 °C. Binding 
experiments, however, were performed on pre-chilled (on ice for 15 min.) cells and 
samples were incubated for 15 min. at 4 °C. Following this, cells were washed with 
imaging medium (DMEM, 20 mM HEPES and 10 % FBS) and imaged by CLSM (SP5 
from Leica, Germany) at 37 °C. 
A lysosomal co-localization of the flu-labeled carrier (FA-PLGA NPs) and cargo 
(ALEXA647siRNA) was determined by an overlay of lysosomal dextran. To label the 
lysosome cells were loaded with 50 µg/mL Dextran-A546 for 2 h. Afterward, cells 
were washed with imaging medium and chased overnight. Between different time 
points, cells were incubated at 37 °C and all settings were kept for all measurements 
within a sample. 
 
7.2.5 Correlative microscopy 
Adenocarcinomic human alveolar basal epithelial cells (A549) were seeded on an 
8-well chamber slide (from SPL) in a density of 30,000 cells/well (= 25,000 cells/cm2) 
in Roswell Park Memorial Institute (RPMI) 1640 medium (from Gibco by Life 
Technologies, USA) supplemented with 10 % FBS. After incubation with FA-labeled 
particles for 24 h the cells were washed with PBS. To fix the cells on the slide, it is 
possible to use 2.5 % glutaraldehyde for 2 h. But because of the relatively strong 
resulting auto-fluorescence the cells were fixed with 3 % para-formaldehyde (PFA; 
prepared by diluting a 16 % stock solution with Milli-Q purified water) for 30 min. 
Here, the creation of a rougher or broken cell surface needs to be considered. After 
the removal of the fixing agent, the cells were washed with PBS buffer, followed by a 
drying sequence with ethanol: 50 % (30 min.) → 60 % (30 min.) → 70 % (30 min.) → 
80 % (30 min.) → 90 % (10 min.) → pure EtOH (10 min.). Finally, 20 µL/well 
Hexamethyldisilazane (HDMS) were applied on the cells and let to evaporate the 
solution. 
 For SEM analysis (for CLSM, see section 7.2.2) 
sputtered on the slide with a very thin gold l
Timed Gold; Quorum Technologies, UK) and examined using a scanning electron 
microscope (Zeiss EVO HD 15, Carl Zeiss AG, Germany) with the associated Zeiss 
SmartSEM® software. 
 
7.3 Results and discussion
7.3.1 Uptake by different cell culture cells
7.3.1.1 Uptake by human
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Figure 7.1 B).  
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7.4 Conclusion 
Comparable with cell-specific differences in transfection efficacy (see Chapter 6) a 
significantly varying uptake behavior of human cancer cell lines (e.g. A549 and 
Calu-3) and human immortalized non-tumor cells (hAELVi) could be observed. 
Non-tumor cells, in general, showed the most limited uptake of all applied NPs 
whereas the amount of internalized particles between cell lines (A549, Calu-3, 
HaCat, NHDF-p and HeLa cells) underlie slighter variations. Here, the cationic 
material of the coated NPs seemed to have a greater impact on the transport of NPs 
into the cell. Incubation with CatStarch-coated NPs resulted in increased fluorescent 
signals at intracellular compartments, followed by FA-PLGA-Prot NPs with some 
fluorescent spots around the nuclear region and a few punctual signals after the 
addition of FA-PLGA-Cs NPs inside the cytosol. As the fluorescence intensity of 
fluorescein is known to be decreased at a lower pH and the fluorescence itself differs 
among the coated NPs (see section 3.3.2.5), a particle quantification based on the 
signal intensities would not be reliable. A specific staining of acidic cell compartments 
(Lysotracker®) successfully dyed endosomes or lysosomes and confirmed the 
internalization of nanoparticles into these cell compartments. 
In principle, FCS experiments confirmed an improved uptake of CatSt-coated and 
Protamine-coated NPs. Additionally, the amount of internalized ALEXA647 was 
visualized and a stronger signal associated with FA-PLGA-Prot NPs (see section 
3.3.2.4) in comparison to FA-PLGA-CatSt NPs, was shown. This means that the 
uptake mechanism is affected by several parameters. To collect more information 
about uptake and localization, however, detailed tracking experiments need to be 
performed. This includes studies focused on the endosomal escape of siRNA 
(regardless of NPs) as siRNA can only act effectively when located in the cytosol.  
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Chapter 8 - Summary and outlook 
 
Within this work different polymer-based nanoparticulate drug delivery systems 
(DDSs) were developed to transport nucleic acids (in specific: siRNA) into the lung to 
overcome the cellular barrier. For this purpose, Chitosan (Cs), a synthesized cationic 
starch derivate (CatStarch) and Protamine (Prot) were chosen as biodegradable 
polymers to coat PLGA nanoparticles (NPs). The established preparation technique 
(emulsion-diffusion-evaporation technique) to create PLGA-Cs nanoparticles was 
applied and could be optimized plus partially automatized. DLS measurements of 
resulting particles obtained a diameter range between 130 and 170 nm, although the 
only changing parameter was the usage of a different cationic polymer. Depending 
on the molecular weight of the polymer different diameters became visible. The 
higher the molecular weight the larger the resulting NPs. Additionally, different 
surface charges could be determined. PLGA-Prot NPs showed a minor ζ-potential of 
14 mV, whereas greater values of 32 mV and 37 mV were measured for PLGA-Cs 
and PLGA-CatSt NPs, respectively. The ζ-potential is presumably referable to the 
amount of protonable amine groups of the polymer. Investigations regarding particle 
stability showed a decreasing surface charge of PLGA-Chitosan NPs after repeating 
washing with water. In contrast to Protamine and Starch, Chitosan seems to have a 
different attachment behavior towards PLGA. Due to weak binding, significant 
amounts of Chitosan were sluiced down. But a specific reason for that could not be 
evaluated and need to be the subject of further studies.  
An absolute quantification of surface-bound siRNA could only be performed for 
PLGA-Chitosan by an indirect UV-quantification and resulted at a loading efficiency 
of 84 %. Fluorometric analyses suffered from quenching effects and unspecific 
binding of fluorescent dyes on unloaded PLGA-Chitosan NPs. Employing gel 
electrophoresis (and replacement of siRNA through heparin) the amount of bound 
siRNA could be measured. As the supernatant of PLGA-Prot NPs contained less 
siRNA than the supernatant of PLGA-Cs NPs and PLGA-CatSt NPs. Most siRNA 
seemed to be bound on PLGA-Prot NPs. However, a quantification method to 
determine the absolute amount of bound API should be found.  
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The developed DDS should be suitable for the desired inhalative application and thus 
be available as a powder or suspension formulation. During stability studies, particles 
were analyzed under different storage conditions and after nebulization (using 
different devices). At a temperature between 4 °C and 20 °C nanoparticulate 
suspensions can be stored for up to 5 weeks. Using lyophilization to create a dry 
powder was unrestrictedly feasible for PLGA-CatSt NPs, whereas PLGA-Prot NPs 
and PLGA-Cs NPs required a cryoprotectant (e.g. Trehalose) to obtain recovered 
NPs after re-dispersion with water. All examined nebulization devices could create a 
fine mist out of the nanoparticulate-suspensions. Especially PLGA-Chitosan NPs 
showed an increased ability to form aggregates by devices using an oscillating 
membrane.   
Moreover, the effect of particles on cells or cell culture models was evaluated. Within 
the applied concentrations no toxic effects based on the addition of NPs could be 
observed. Merely a slight activation of dendritic cells for all formulations at higher 
concentrations became visible. However, this activation could not be attributed to an 
activation of TLR2 and 4. As the developed DDSs were made to bind nucleic acids, 
positive controls for TLR3, 7 and 9 (dsRNA, ssRNA, and CPG DNA) were attached to 
the particulate system possible non-activation could not be excluded. The presence 
of bound siRNA resulted in no differing observations.  
Finally, the efficiency of a transport system to convey the siRNA into the cell was 
crucial. As no stable transfected cell line was available, a co-transfection method was 
developed to enable the detection of a decreased expression of Luciferase. 
However, the received results were not only influenced by the particle load or the 
buffering capacity (for release from endosomes) of the polymer. In addition, polymer-
siRNA interactions were responsible for successful transfections. A drawback of this 
method is the necessary use of transfection agents. Consequently, obtained results 
need to be confirmed by transfection studies on stably transfected cell lines or a 
knock-down and quantification of GAPDH via qPCR. CLSM measurements showed 
an uptake of fluorescent labeled NPs into different cells and localization at 
endosomes/lysosomes, although particles tend to attach to the cell membrane. 
Recapitulating three promising carrier systems for the transport of nucleic acids with 
differing characteristics could be developed and analyzed. Prospective, transfection 
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studies of nebulized NPs on cellular co-culture (e.g hAELVi + THP-1) or inflamed 
in-vitro models will be possible followed by in-vivo inflammation models (e.g. TNFα)  
and biodistribution studies to identify regions where NPs may accumulate. 
Additionally, as soon as a suitable transgenic mouse model with luciferase 
expression in the lung is build up and the corresponding siRNA is available, in-vivo 
transfection studies will represent an important milestone for the development of a 
novel DDS. 
 Chapter 9 – Zusammenfassung und Ausblick 
 
 
132 
Chapter 9 - Zusammenfassung und Ausblick 
Im Rahmen dieser Arbeit wurden verschiedene polymerbasierte nanopartikuläre 
Transportsysteme entwickelt, mit dem Ziel Nukleinsäuren (im Speziellen: siRNA) in 
die Lunge zu transportieren, um dort die zelluläre Barriere zu überwinden. Zu den 
ausgewählten bioabbaubaren Polymeren gehörten neben Chitosan (Cs), eine eigens 
synthetisierte kationische Stärke (CatSt) und Protamin (Prot). Eine bereits etablierte 
Methode (Emulsions-Diffusions-Verdunstungs-Methode) zur Herstellung von 
Chitosan-überzogenen PLGA Nanopartikeln konnte optimiert und teilweise 
automatisiert werden. Zusätzlich war eine Übertragung dieser Methode auf weitere 
eingesetzte Polymere (hier: Prot und CatSt) möglich. Die resultierenden Partikeln 
wurden analysiert und miteinander verglichen. Dynamische Streulichtmessungen 
ergaben trotz identischer Mengen an eingesetztem Polymer, Partikeldurchmesser 
zwischen 130 und 170 nm. Diese erheblichen Größenunterschiede konnten durch 
die jeweiligen Molekulargewichte erklärt werden. Je höher das Molekulargewicht des 
kationischen Polymers, desto größer die PLGA-basierten Nanopartikel (NP). Des 
Weiteren wurden Abweichungen bei der Oberflächenladung festgestellt. PLGA-Prot 
NPs zeigten mit 14 mV das geringste ζ-Potential, wohingegen bei PLGA-Cs und 
PLGA-CatSt NPs mit jeweils 32 mV und 37 mV höhere Werte gemessen wurden. 
Dies ist voraussichtlich auf die unterschiedliche Anzahl protonierbarer Amine im 
Polymer zurückzuführen. Untersuchungen auf Partikelstabilität zeigten eine sinkende 
Oberflächenladung von ausschließlich PLGA-Cs NPs nach mehrmaligem Waschen 
mit Wasser. Chitosan scheint somit im Vergleich zu Prot und CatSt ein anderes 
Bindungsverhalten zum PLGA zu besitzen. Durch die schwache Bindung zu PLGA 
konnte eine große Menge an Polymer abgewaschen werden. Die konkrete Ursache 
konnte noch nicht in Gänze analysiert werden und bedarf daher weiterer 
Nachforschungen.  
Eine absolute Quantifizierung der oberflächengebundenen siRNA war nur bedingt 
durchführbar. Eine indirekte UV-Quantifizierung freier siRNA im umgebenen Medium 
konnte nur bei PLGA-Cs NPs erreicht werden und ergab eine Beladungseffizienz 
(LE) von circa 84 %. Eine fluorimetrische Analyse war aufgrund von 
Quenchingeffekten und einer unspezifischen Bindung von Fluoreszenzfarbstoffen an 
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unbeladenen PLGA-Cs NPs ausgeschlossen. Mittels Gelelektrophorese konnte 
jedoch (nach Verdrängung der siRNA durch Heparin) die gebundene Menge an 
siRNA bestimmt werden. Da der Überstand von PLGA-Prot NPs die geringste Menge 
siRNA und der von PLGA-CatSt NPs die größte Menge enthielt, scheint der Hauptteil 
an siRNA auf der Oberfläche von PLGA-Prot NPs gebunden zu sein. Hier konnten 
lediglich vergleichende Aussagen getroffen werden, wobei eine geeignete 
Quantifizierungsmethode zur absoluten Bestimmung gebundener siRNA nicht zur 
Verfügung stand und entwickelt werden müsste.   
Die entwickelten Partikel sind für eine spätere Anwendung in der inhalativen 
Therapie vorgesehen und sollten daher als Pulver oder Flüssigformulierung vorliegen 
können. Innerhalb der Stabilitätsstudien wurde sowohl Lagerungsverhalten über die 
Zeit, als auch die Partikelstabilität nach Vernebelung mit verschiedenen 
Gerätschaften untersucht. Bei Temperaturen zwischen 4 und 20 °C ist die Lagerung 
einer Nanopartikelsuspension bis zu 5 Wochen möglich. Die Herstellung eines 
Lyophilisats (als lagerfähige oder finale Formulierung) ist hingegen nur 
uneingeschränkt für PLGA-CatSt sinnvoll. Die beiden anderen Systeme benötigen 
die Zugabe eines Cryoprotectants (z.B. Trehalose) wobei die Eigenschaften von 
PLGA-Cs NPs nicht mehr vollständig wiederhergestellt werden konnten. Bei der 
Verwendung von oszillierenden Membranen zur Vernebelung traten durch die 
applizierten physikalischen Kräfte im Allgemeinen vermehrt Aggregationen auf. 
Des Weiteren wurde sich mit dem Einfluss von Partikeln auf Zellen bzw. 
Zellkulturmodellen befasst. In den eingesetzten Mengen konnte eine Zellschädigung 
durch die Zugabe von NPs ausgeschlossen werden. Eine leichte Aktivierung 
dedritischer Zellen durch alle drei Systeme konnte zwar in höheren Konzentrationen 
beobachtet werden, war allerdings nicht auf eine Aktivierung von TLR2 und 4 
zurückzuführen. Eine fehlende Aktivierung von TLR3, 7 und 9 konnte aufgrund von 
Bindungstendenzen zu den Positivkontrollen (dsRNA, ssRNA and CPG DNA) nicht 
ausgeschlossen werden. Dies war allerdings zu erwarten, da die entwickelten 
Transporter Nucleinsäuren an der Partikeloberfläche binden sollen. Eine Beladung 
mit siRNA führte zu keinerlei abweichenden Ergebnissen.  
Letztendlich ist die Effektivität eines Transportsystems, um enthaltene siRNA in die 
Zelle zu befördern, entscheidend. Da bis zum Ende der Ausarbeitung keine 
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geeignete, stabil transfizierte Zelllinie zur Verfügbar stand, konnte mittels einer 
simultanen Co-Transfektion eine verminderte Expression des eingeschleusten 
Luciferase-Plasmids sichtbar gemacht werden. Die Resultate sind jedoch nicht 
alleinig auf eine möglichst hohe Beladung oder eine verbesserte Pufferkapazität 
(Freisetzung aus Endosomen) zurückzuführen. Das Zusammenspiel aus Beladung, 
Pufferkapazität und Polymer-siRNA-Interaktion scheint gemeinsam für die 
Transfektionseffizienz verantwortlich zu sein. Da eine Co-Transfektion jedoch dem 
Einsatz von Transfektionsreagentien bedarf, ist eine Bestätigung dieser Ergebnisse 
durch den Einsatz einer stabil transfizierten Zelllinie oder eine Bestimmung von 
GAPDH mittels qPCR unabdingbar. 
Eine Aufnahme von Fluoreszenz-markierten NPs in die Zelle und eine Lokalisierung 
in Endosomen/Lysosomen konnte mittels CLSM gezeigt werden, wenn gleich ein 
Großteil der Partikel sich an der Außenmembran der Zelle anlagerten. 
Zusammenfassend konnten demnach drei vielversprechende Trägersysteme 
entwickelt und beschrieben werden. Neben Versuche zur Bestätigung der 
Co-Transfektionsergebnisse, können Studien auf Co-Kultur-Zellmodelle (bsp. hAELVi 
+ THP-1) oder auf krankhafte bzw. entzündete Zellmodelle ausgeweitet werden. Ein 
Aufbringen von vernebelten Transportsystemen ist ebenfalls vorstellbar. Folgen 
sollten dann auch in-vivo Studien zur Verteilung der Partikel im Körper von Mäusen, 
um mögliche Ansammlungen von Partikeln und eine einhergehende Belastung von 
Organen zu identifizieren. Sobald ein geeignetes TNFα-Tiermodell mit transgenen 
Mäusen und die dazugehörige siRNA verfügbar sind, bilden solche in-vivo 
Transfektionsstudien einen wichtigen Meilenstein bei der Entwicklung neuartiger 
Trägersysteme.  
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Abbreviations 
 
AFM   atomic force microscopy = scanning force microscopy (SFM) 
ALI   air-liquid interface 
API   active pharmaceutical ingredient 
ASO   antisense oligonucleotide 
ATR   attenuated total reflectance      
   (sampling technique in IR spectroscopy) 
A549   adenocarcinomic human alveolar basal epithelial cells 
BCA   bicinchoninic assay 
BCA-RAC  bicinchoninic assay reactive agent compatible 
BP   biopharmaceuticals 
BPE   bovine pituitary extract    
BSA   bovine serum albumin 
BSA-FAF  bovine serum albumin, fatty acid free 
CA   cellulose acetate 
CatStarch  cationic starch derivative (own synthesis) 
CCLR   cell culture lysis reagent 
CDx   cluster of differentiation x (x = 4, 40, 86, 11c) 
COMPACT Collaboration on the Optimization of Macromolecular 
Pharmaceutical Access to Cellular Targets 
COPD chronic obstructive pulmonary disease 
Cs Chitosan 
CTA cellulose triacetate 
DAPI 4',6-diamidino-2-phenylindole 
DC   dendritic cell 
DEPC   Diethy pyrocarbonate = diethyl dicarbonate 
DiI 1,1‘-Dioctadecyl-3,3,3‘,3‘-tetramethylindocarbocyanine 
perchlorate 
DLS Dynamic light scattering = photon correlation spectroscopy (PCS) 
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DMEM Dulbecco’s Modified Eagle Medium 
DNA   deoxyribonucleic acid 
dog   drop on grid 
dsRNA  double-stranded RNA 
DTT   dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
EFPIA  European Federation of Pharmaceutical Industries  
   and Associations 
EMA   European Medicines Agency 
FA   fluoresceinamine 
FBS   fetal bovine serum = fetal calf serum (abbreviated ‘FCS’) 
FCS   fluorescent correlation spectroscopy 
FDA   Food and Drug Administration 
FSC   forward scatter 
GA   gentamicin amphotericin 
god   grid on drop 
hAELVi  human alveolar epithelial lentivirus immortalized 
HBSS   Hank’s Balanced Salt Solution 
HDMS  hexamethyldisilazane = Bis(trimethylsilyl)amine 
HEK293  human embryonic kidney 293 cells 
HIPS   Helmholtz-Institute for Pharmaceutical research Saarland 
Hsp70  heat shock proteins, 70 kDa 
IMI   Innovative Medicine Initiative 
IR   infra-red         
   (spectral range: ~14,000 cm-1 to 10 cm-1 or 1 mm to 800 nm) 
KRB   Krebs-Ringer Buffer 
LC   loading capacity 
LDH   lactate dehydrogenase 
LE   loading efficiency  
LF iMAX  Lipofectamine® RNAiMax 
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LCC   liquid covered conditions 
LPS   lipopolysaccharide (endotoxin) 
mBMDC  murine bone marrow-derived dendritic cells 
MHCII   major histocompatibility complex class II 
mRNA  messenger RNA 
miRNA  micro RNA 
MMD   mass mean diameter 
MTT   methyl-thiazoyl-tetrazolium 
MW   ‘relative’ molecular weight or mass 
MWCO  molecular weight cut-off 
NF-кB   nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
nt   nucleotides  
NTA   nanoparticle tracking analysis 
PAGE   polyacrylamide gel electrophoresis 
PBS   Phosphate Buffered Saline 
PCS   Photon correlation spectroscopy = dynamic light scattering (DLS) 
PDI   polydispersity index 
PES   polyethersulfone 
pDNA   plasmid DNA 
PEG   polyethylene glycol 
PEI   polyethyleneimine 
PES   polyethersulfone 
PFA   paraformaldehyde 
piRNA  piwi-interacting RNA 
PIWI or piwi  P-element induced wimpy testis 
PLGA   Poly(lactic-co-glycolic acid) 
PLGA-CatSt  CatStarch-coated PLGA NPs 
PLGA-Cs  chitosan-coated PLGA NPs 
PLGA-Prot  protamine-coated PLGA NPs 
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PMA   phorbol 12-myristate 13-acetate 
Prot   Protamine 
P/S   penicillin streptomycin 
PVOH   polyvinyl alcohol 
rasiRNA  repeat associated small interfering RNA 
RC   regenerated cellulose 
rhEGF  recombinant human Epidermal Growth Factor 
RISC   RNA-induced Silencing Complex 
RLU   relative light units 
RNA   ribonucleic acid 
RNAi   RNA interference 
rpm   revolutions per minute 
RPMI   Roswell Park Memorial Institute 
RT   room temperature [20 °C] 
SAGM  Small Airway Growth Medium 
SDS   sodium dodecylsulfate 
SEC   size exclusion chromatography 
SEM   scanning electron microscopy 
SFM   scanning force microscopy = atomic force microscopy (AFM) 
shRNA  short hairpin RNA 
siRNA   small interfering RNA 
SPM   scanning probe microscopy (e.g. AFM or SFM) 
SSC   side scatter 
ssRNA  single-stranded RNA 
TAE   TRIS/Acetic acid/EDTA 
TBE   Tris/Borate/EDTA 
TE   Tris/EDTA 
TEER   transepithelial electric resistance 
TLR   toll-like receptor 
  Abbreviations 
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TNF   tumor necrosis factor 
UV   ultraviolet 
VMD   volumetric mean diameter 
WP   work package 
ZP   zeta potential 
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